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ABSTRACT 
Nicole Lane Davis: Adherence-related mechanisms of breastmilk HIV-1 transmission 
(Under the direction of William C. Miller) 
  
  Postpartum HIV transmission through breastfeeding accounts for up to 44% of infant HIV 
infections. Antiretroviral (ARV) drugs are administered to either the HIV-infected mother or HIV-exposed 
infant throughout breastfeeding to reduce HIV transmission risk. Suboptimal adherence to prescribed 
ARV regimens may partly explain breastmilk HIV transmission despite ARV use. The purpose of this 
dissertation was to 1) estimate adherence to postpartum ARVs, 2) quantify the effect of postpartum 
adherence on breastmilk HIV transmission, and 3) evaluate breastmilk HIV RNA concentration as a 
mediating factor between ARV adherence and breastmilk HIV transmission. 
  We included mother-infant pairs randomized to receive 28 weeks of either triple maternal ARV 
or daily infant nevirapine as part of the Breastfeeding, Antiretrovirals, and Nutrition study. Among these, 
a cohort of 1479 mother-infant pairs was used to estimate the association between postpartum ARV 
adherence and breastmilk HIV-1 transmission between 5-38 weeks of age. Additionally, a case-cohort 
study including 263 mother-infant pairs was used to assess breastmilk viral load as a mediating factor 
between postpartum adherence and breastmilk HIV transmission. Adherence was measured over four 
time intervals using pill count, suspension bottle weight, and maternal self-report. RNA concentration 
was measured in both plasma and breastmilk at 5 time points. Infant HIV-1 infection was determined by 
DNA PCR every 2-6 weeks.  
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Using pill count and bottle weight information, having >90% adherence was associated with a 
52% (95% CI 3-76%) relative reduction in the adjusted rate of breastmilk HIV-1 transmission by 38 weeks 
of age, compared with having <90% adherence. Having partial adherence (81-98%) was associated with 
a 77% (95% CI 33-92%) relative reduction in the adjusted odds of having detectable (>40 copies/ml) 
breastmilk HIV RNA, compared with having poor adherence (0-80%). Detectable breastmilk HIV RNA was 
associated with 4.5 (95% CI 2.0-9.9) times the adjusted relative rate of BMK HIV-1 transmission by 28 
weeks of infant’s age, compared to having undetectable (<40 copies/ml) breastmilk HIV RNA. 
Maternal ARV adherence is associated with reduced breastmilk HIV transmission, at least partly 
mediated by reduced breastmilk HIV RNA. Effective adherence interventions may help to further 
prevent breastmilk HIV transmission. 
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CHAPTER ONE: SPECIFIC AIMS 
 
Prevention of mother-to-child HIV transmission (PMTCT) is one of the HIV research arena’s 
biggest success stories.(1-12) We know from controlled studies that intrauterine and intrapartum 
transmission can be reduced by more than 80%; and postpartum transmission through breastfeeding 
can be reduced more than 70% by extended postpartum antiretroviral prophylaxis.(7, 8, 12) Despite 
these extraordinary scientific achievements and wide implementation of basic PMTCT interventions, 
implementation of more complex and efficacious interventions has been challenging in resource-limited 
settings.(13-15) Postpartum prophylaxis during breastfeeding is promising, but could be improved by 
understanding the extent to which adherence needs to be maintained during this extended period, and 
how suboptimal adherence affects transmission.(14)  
 
The Breastfeeding, Antiretrovirals, and Nutrition (BAN) clinical trial was conducted in Malawi 
between 2004 and 2010 using a factorial design.(7) Mothers were randomized to receive a lipid-based 
nutrient supplement. All mothers and infants received one dose of nevirapine (NVP) and seven days of 
zidovudine and lamivudine. Mother-infant pairs were randomized to also receive one of three 
postpartum ARV regimens: 1) maternal triple ARV throughout breastfeeding; 2) infant NVP throughout 
breastfeeding; or 3) no further drugs postpartum (“enhanced” control). Infants randomized to maternal 
ARV and infant NVP experienced a 2.9% and 1.7% risk of HIV infection between 2 and 28 weeks of age, 
respectively.(7) Despite well-controlled implementation of an efficacious prophylaxis regimen, 
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breastmilk HIV transmission still occurred. One possible explanation for transmission could be 
suboptimal adherence to the prescribed antiretrovirals, which in turn can affect plasma drug 
concentrations and the duration and rate antiretrovirals suppress viral replication (pharmacokinetics). 
Continued viral replication results in increased HIV viral load, and higher viral loads have been 
associated with greater risk of HIV transmission.(16) Understanding the association between adherence, 
viral load, and resulting HIV transmission is critical. 
 
Using clinical data along with stored plasma and breastmilk specimens from BAN, we estimated 
the association between postpartum antiretroviral adherence and the following: plasma HIV RNA 
concentration (viral load or VL), breastmilk HIV VL, and subsequent breastmilk HIV infection. In addition, 
we considered the following contrasts: plasma HIV RNA and breastmilk HIV RNA, and breastmilk HIV 
RNA and breastmilk HIV transmission. BAN provided a unique opportunity to conduct this ancillary study 
in a timely and cost-efficient manner. We used more frequent measures of the time-varying exposure 
(adherence) and outcomes (plasma and breastmilk viral load, transmission) than previously reported 
studies. In addition, we provided the first estimates of: adherence to an extended infant NVP regimen 
using the objective measure of suspension bottle weights, the association between postpartum 
adherence and breastmilk transmission, and the association between postpartum adherence and 
breastmilk viral load. 
 
Quantifying the association between postpartum ARV adherence and breastmilk HIV 
transmission has significant practical implications for roll-out of World Health Organization (WHO) 
PMTCT guidelines for resource-limited settings, which promote extended antiretroviral prophylaxis until 
complete cessation of breastfeeding and beyond.   
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 Aim 1.  Estimate the association between postnatal maternal and infant antiretroviral 
adherence and breastmilk HIV transmission between 5 and 38 weeks of life.  
Hypothesis: Suboptimal adherence (<90%) results in increased breastmilk transmission of HIV.  
Overview:  This prospective cohort study consisted of mother-infant pairs enrolled in BAN and randomly 
assigned to the two treatment arms. Adherence was measured by maternal ARV pill count, infant NVP 
suspension bottle weight, and maternal self-report.     
 
Aim 2.  Estimate the association between postpartum maternal antiretroviral adherence, 
plasma HIV viral load, breastmilk HIV viral load, and breastmilk HIV transmission between 2 and 28 
weeks of life. 
Hypothesis:  Suboptimal adherence (<80%) results in increased plasma and breastmilk HIV RNA, and 
increased HIV transmission via breastmilk.  
Overview:  A case-cohort study design was employed. All HIV-infected infants were considered cases; a 
15% subsample of HIV-uninfected infants served as non-cases. Plasma and breastmilk specimens taken 
at 2, 6, 12, 18, and 24 weeks were used for viral load analyses.   
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CHAPTER TWO: BACKGROUND AND SIGNIFICANCE 
 
Prevention of mother-to-child HIV transmission 
Incidence of perinatal HIV infection has declined in recent years, but still remains a significant 
public health problem.(17) In 2009, 370,000 children were infected with HIV through mother-to-child 
transmission; down from 500,000 estimated vertical transmissions in 2001.(18) While this 25% reduction 
in transmissions shows progress, greater reductions are achievable given current knowledge. This 
“impact gap” is greatest in sub-Saharan Africa, which bears the brunt of the pediatric HIV epidemic with 
90% of vertical transmissions occurring in the region.(18)  
 
Without any intervention, 25-45% of HIV-exposed infants will become HIV infected either in-
utero, during labor and delivery, or through breastfeeding.(19, 20) Transmission can occur through fetal 
contact with HIV viral particles or HIV-infected immune cells found in one or more of the following: 
maternal blood, cervical or vaginal secretions, and breastmilk.(21) In-utero transmission is thought to 
occur in less than 10% of HIV-infected pregnant women, and may occur via transplacental crossing of 
blood, though this has not been proven.(22) The greatest proportion of infections occur during the 
intrapartum period, when the fetus may experience prolonged contact with virus found in maternal 
blood and/or cervical and vaginal secretions.(22) However, postpartum transmission through 
breastfeeding has been shown to account for up to 44% of infant infections, with the majority of 
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infections occurring in the first few months of life.(23) Breastmilk transmission is thought to occur when 
infant ingestion of cell-free or cell-associated virus in breastmilk is absorbed in mucosal gut surfaces, 
tonsils, or adenoids.(20)  
 
Advanced maternal immune deficiency, prolonged rupture of the amniotic membranes, and 
extended breastfeeding are some of the factors associated with an increased risk of vertical 
transmission during various stages of the peripartum period (Table 2.1).(21, 24-27) However, high 
maternal viral load, possibly due to acute infection or advanced disease, is among the most important 
risk factors for transmission during pregnancy and breastfeeding.(16, 24, 28, 29) Transmission potential 
is thought to be virtually 0% at plasma HIV RNA concentration less than 1,000 copies/ml, and increase to 
over 40% at a plasma HIV RNA concentration of more than 100,000 copies/ml.(16) Most successful 
PMTCT interventions have focused on reducing fetal exposure to the virus, either by avoiding labor and 
delivery via elective caesarian section, avoiding breastfeeding via use of infant formula, or by reducing 
viral replication through use of antiretroviral medications. 
                
Initially, PMTCT programs in the developing world only used antiretrovirals to reduce in-utero 
and intrapartum HIV transmission. To limit postpartum transmission, mothers were encouraged to 
replacement feed if acceptable, feasible, appropriate, sustainable and safe (AFASS), or to exclusively 
breastfeed and wean early.(30) While antiretrovirals substantially reduced peripartum transmissions, 
postpartum transmissions still occurred at a relatively high rate.(13) HIV-free survival (proportions of 
infants that were alive and free of HIV) between formula-fed and breast-fed HIV-exposed infants proved 
to be similar by feeding choice.(31) Gains made in reducing vertical HIV transmission by avoiding 
breastfeeding were met with increases in death due to mixing formula with unsafe water, improper 
 
 
6 
 
hygiene, and a lack of breastmilk immunologic benefit.(27, 31) Reducing breastmilk HIV transmission 
while encouraging mothers to breastfeed gained focus and research attention, resulting in several 
randomized trials that assigned mother-infant pairs to postpartum antiretroviral prophylaxis or 
treatment until complete cessation of breastfeeding.(4, 6-8) Extending antiretrovirals through the 
breastfeeding period proved to be safe and effective at dramatically reducing postpartum HIV 
transmission via breastmilk, and is now recommended by WHO.(32)   
 
ARV adherence and virological suppression 
Achieving and maintaining virological suppression is dependent on adherence to prescribed 
regimens, as demonstrated in HIV-infected adults.(33) The class of ARV drug is thought to determine the 
level of adherence needed to maintain virological suppression, but it is unclear what level of adherence 
is needed to become and remain virologically suppressed in the late ARV era of boosted protease 
inhibitors and ultrasensitive measures of viral load.(34)  
 
Greater than 95% adherence is thought to be needed to maintain virological suppression among 
a minimum of 80% of patients when unboosted protease inhibitors are included in the ARV regimen.(35) 
Pharmacokinetic boosting of protease inhibitors (PI) with drugs such as ritonavir has been used to 
extend the plasma half-life of the active PI (i.e. lopinavir) by inhibiting drug metabolism during 
absorption, and also in the liver.(36, 37) With boosted PIs, 80% adherence may be sufficient for a 
minimum of 80% of patients to achieve virological suppression.(38-40) In contrast, the adherence 
needed for non-nucleoside reverse transcriptase inhibitor (NNRTI) based regimens is less 
understood.(36)  NNRTIs typically have a longer half-life than PIs, resulting in potential mono-therapy 
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and development of drug resistance if patients are non-adherent for extended periods of time.(36) In 
that PIs have a high genetic barrier to resistance, they are often thought to be more ‘forgiving’ than 
NNRTIs.(36)   
 
While much is known about adherence in HIV-infected adults, less is known about adherence to 
PMTCT regimens, including extended regimens to prevent breastmilk transmission. Among pregnant 
women, non-adherence was associated with higher HIV viral loads in two United States studies, and 
compliance to short-course zidovudine was associated with decreased vertical transmission in a Kenyan 
study.(41-43) However, information on postpartum adherence and adherence-related outcomes in 
resource-limited settings is scant. To address this knowledge gap, we assessed the effects of adherence 
to both NNRTI and PI-based postpartum ARV regimens on virological suppression and HIV transmission 
in a resource-limited setting. 
 
Maternal and infant adherence to antiretroviral drug regimens. 
Adherence to short-course and extended antiretroviral regimens may be measured using a 
variety of approaches ranging in sophistication, including the following: self-report, pill count, electronic 
pill-boxes, visual analog scale, pharmacy dispense records, patient attendance at scheduled medical 
visits, and measurement of blood drug levels.(44) None of the adherence measurement approaches are 
completely accurate, and most are not practical for routine use in clinical settings.(45) Self-reported 
adherence has the most potential for bias (usually in the form of overestimating adherence) due to 
recall and social desirability bias, but is the measurement tool most often used because it is easy and 
inexpensive to administer.(46) Adherence measurements based on pill count and suspension bottle 
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weight are thought to have greater validity and take into account adherence over the entire monitoring 
period, rather than just the three days prior to the self-report assessment visit.(47) More expensive and 
sophisticated methods of adherence measurement, such as electronic pill-boxes, may have even greater 
validity.(47) However, they do not account for the possibility of removing medication doses in advance, 
and are not available for routine use in Malawi. Assays of drug levels to determine ARV adherence have 
been sparingly used, and only in clinical trial settings. Expense and the need for highly trained laboratory 
personnel and specialized equipment contribute to their scant use. Plasma drug levels are also limited to 
the period of time right before the clinic visit, and when used alone provide limited data.(47) We used 
pill count and suspension bottle weight data taken at multiple visits as our main adherence measure. In 
sensitivity analyses, we compared pill count and bottle weight adherence with maternal self-reported 
adherence. Both pill count and self-report are thought to be feasible for implementation in resource-
limited settings.  
 
Adherence to combination ARV may be lower than adherence to simpler but less efficacious 
PMTCT regimens, according to pooled data from multiple PMTCT studies.(48) Several reasons for non-
adherence to ARV and PMTCT regimens have been cited, including: time and financial costs of accessing 
care, stigma, forgetfulness or changes in routine, and side effects of medications.(43, 49-54) Continued 
exposure over time to structural and economic barriers, stigma, and routine barriers such as medication 
side effects or changes in routine may contribute to adherence decay with prolonged ARV, compared to 
short-course regimens. Ensuring gains in efficacy are not countered by deteriorating adherence-affected 
outcomes is paramount.    
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Adherence to extended infant nevirapine has only been sparingly estimated, with no known 
studies to date assessing infant adherence using suspension bottle weight. The same barriers that 
contribute to declines in postpartum adherence to maternal ARV may also lead to reductions in 
adherence to infant NVP during the breastfeeding period. If mothers are not receiving postpartum 
antiretrovirals, then adherence to extended infant NVP regimens until complete cessation of 
breastfeeding is critically important. Understanding the levels of infant adherence maintained during 
breastfeeding, and how they affect adherence-related outcomes is needed.   
 
Postpartum adherence to PMTCT regimens was shown to be lower than antepartum adherence 
in the United States, but in resource limited settings, postpartum adherence is largely unknown.(41, 43, 
55) A postpartum decline in adherence may be caused by several different factors, including, increased 
stress and changes in routine related to caring for a newborn, and concern over the newborn’s HIV 
status.(56) Decreased adherence among HIV-positive adults has been associated with time since HIV 
diagnosis and duration of time on ARVs, which may also contribute to postpartum adherence decline in 
the era of extended prophylaxis through breastfeeding.(56) In that declines in adherence during the 
postpartum period have been seen in some settings, it is imperative to know the implications for sub-
optimal postpartum adherence on HIV transmission during the critical breastfeeding period.  
 
Only approximately 53% of women have adherence levels > 80% during the postpartum period, 
according to a recent meta-analysis.(48) Therefore, nearly half of postpartum women had adherence 
levels below the current recommended level for virological suppression even when boosted protease 
inhibitors are used. Nonadherence has been associated with increased HIV viral load among pregnant 
women in the United States.(41, 43) However, the effect of nonadherence on MTCT has only been 
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evaluated in one resource-limited setting, which found that women who were compliant to a short-
course zidovudine regimen tended to have a lower transmission rate compared to those who were non-
compliant.(42) This was the first study to assess the effects of sub-optimal postpartum adherence on 
both plasma and breastmilk HIV viral load and HIV transmission in a resource-limited setting. 
 
Adherence and antiretroviral pharmacokinetics 
Adequate therapeutic levels of antiretrovirals are needed to suppress viral replication and 
prevent development of resistance.(33) The degree of adherence to ARV regimens is directly related to 
the maintenance of adequate therapeutic antiretroviral levels.(33) However, even with adequate 
adherence, inter-patient drug exposure may vary due to differences in absorption, distribution, 
metabolism and elimination. While there are some data on ARV adherence and virological suppression, 
the level of adherence needed to maintain therapeutic drug levels, an important intermediary step, is 
not well known.(57)  
 
Adherence and breastmilk HIV transmission 
To date, the level of adherence needed for postpartum maternal ARV regimens or extended 
infant NVP to prevent breastmilk HIV transmission has not been studied. While both maternal ARV and 
extended infant NVP have been efficacious in drastically reducing transmission rates, transmissions have 
still occurred even in closely monitored clinical trials.(4, 6-8, 58)  Adherence has remained a well-
documented challenge for HIV treatment in general, and specifically in PMTCT programs. The effect of 
adherence on breastmilk HIV transmission is important for prevention programming, and currently not 
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well understood. We quantified the effect of adherence to both maternal ARV and extended infant NVP 
on breastmilk transmission of HIV.   
 
Several factors affect an infant’s exposure to antiretrovirals through breastfeeding, and include 
the following: concentration of drug in the mother’s plasma, amount of drug excreted into the 
breastmilk, and the amount of milk the infant ingests.(57) Drug disposition during the postpartum 
period can be unpredictable due to the physiologic changes that take place during pregnancy which 
affect drug disposition, and the intra-subject variability in the time it takes for these changes to revert 
back to pre-pregnancy levels.(57) In addition, two potential mechanisms are thought to be at play 
regarding virus populations in breastmilk. The first, which is thought to constitute the largest proportion, 
is by continual trafficking from blood into breastmilk of cell-associated virus which resides inside the cell 
(measured as HIV-DNA), or cell-free virions (measured as HIV-RNA).(59) The second is transient local 
production of virus in the breastmilk.(59, 60) To further add to the complexity, there are differential 
levels of antiretroviral exposure into breastmilk and infant plasma both within and between classes of 
drugs.(57) Only ZDV and 3TC have concentrated to any real extent in breastmilk, among the ARVs that 
have been evaluated to date.(60) In addition, ARV has been shown to suppress HIV RNA in plasma and 
breastmilk, while HIV DNA in breastmilk persisted.(60) These challenges have resulted in incomplete 
knowledge regarding the antiretroviral therapeutic levels that are needed to prevent drug resistance to 
the infant, and to ultimately prevent breastmilk HIV transmission. However, adherence to ARV regimens 
is undoubtedly required if therapeutic levels of antiretrovirals are going to be achieved and maintained.   
 
  
 
 
12 
 
Summary 
Mother-to-child transmission of HIV has been greatly reduced, but challenges still remain.(15) 
WHO recently revised their PMTCT guidance for resource-limited settings, and now recommend all HIV-
infected pregnant and breastfeeding women receive maternal antiretroviral treatment through the 
breastfeeding period and beyond.(32) Effective implementation of the revised WHO guidance relies on 
adherence to prescribed antiretroviral regimens.(32) Maintaining adherence to even short-course 
antiretroviral prophylaxis has been challenging for PMTCT programs in resource-limited settings.(54, 61-
64) Adherence to more efficacious and complex maternal ARV regimens has been even lower than 
adherence to short-course PMTCT regimens, with almost half of HIV-positive mothers not maintaining 
an adherence level thought to be needed for virological suppression.(48) Being virologically suppressed 
has been widely shown to reduce the risk of HIV transmission.(16) Adherence is needed to achieve and 
maintain therapeutic levels of antiretrovirals in plasma, inhibit viral replication, and achieve viral 
suppression.(33)    
 
We used a comprehensive approach for assessing the role of adherence on HIV transmission by 
assessing the causal pathway that includes both plasma and breastmilk HIV viral load. Greater 
understanding of the interconnectedness between adherence, viral load, and HIV transmission is a 
major step in eradicating breastmilk HIV transmission, and making breastfeeding safe for all infants. In 
addition, the data are of great importance to national PMTCT programs as they implement the revised 
WHO guidance and evaluate their adherence counseling messages.   
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Table 2.1 Selected important risk factors for vertical HIV transmission by peripartum period. 
Stage Risk Factors 
Pregnancy High HIV viral load (acute infection, advanced disease) 
Low CD4 count 
Other infections (e.g..: Hepatitis C, CMV, STIs) 
 
Labor & Delivery High maternal HIV viral load  
Prolonged rupture of membranes 
Preterm delivery (especially <32 weeks) 
Vaginal delivery 
Chorioamnionitis (inflammation of fetal membranes due to bacterial infection) 
 
Breastfeeding High maternal HIV viral load  
Low maternal CD4 count 
Maternal illness 
Non-exclusive breastfeeding 
Prolonged breastfeeding 
Cracked nipples, mastitis 
Infant co-infections 
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CHAPTER THREE: RESEARCH DESIGN AND METHODS 
 
PARENT STUDY 
The Breastfeeding, Antiretroviral and Nutrition (BAN) randomized control trial was conducted in 
Malawi between 2004 and 2010 to assess in part the benefit and safety of antiretroviral medications 
given either to infants or to their mothers to prevent HIV transmission during breastfeeding.(7)  Mothers 
were recruited at antenatal clinics in Lilongwe, Malawi where HIV testing was conducted.  Eligibility 
criteria for mother-baby pairs included the following: maternal HIV infection, maternal CD4 > 250 
cells/µL (> 200 cells/ µL before July 24, 2006), have used no antiretroviral drugs previously (including SD 
NVP), infant birth weight of at least 2000 grams, no infant or maternal condition that would preclude 
the use of a study drug, and able to be enrolled within 36 hours of delivery.(7)   
 
All mothers and infants enrolled in BAN received a single dose of NVP along with seven days of 
zidovudine and lamivudine postpartum.  In addition, mother-infant pairs were randomized to receive 
one of the following PMTCT prophylaxis regimens postpartum: 1) 28 weeks of a triple antiretroviral 
regimen given to the mother only (maternal ARV); 2) 28 weeks of daily nevirapine given to the infant 
only (infant NVP); or 3) no further drugs postpartum (enhanced control).(7)   
 
Infant dried blood spots (DBS) were collected at labor and delivery, 1, 2, 4, 6, 8, 12, 18, 24, 28, 
32, 36, 42 and 48 weeks of age, and were used to narrowly define the time of infant HIV infection by 
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polymerase chain reaction (PCR).  In addition, maternal plasma and breastmilk specimens were obtained 
at labor/delivery, 2, 4, 6, 8, 12, 18, and 24 weeks postpartum. Maternal plasma continued to be 
collected at 28, 36, and 48 weeks postpartum.  Infant plasma was collected at birth, 2, 6, 12, 18, 24, 28, 
36, and 48 weeks. Self-reported adherence data was collected at 1, 4, 8, 21, and 28 weeks postpartum, 
using three-day recall; pill counts and bottle weights were calculated at 2, 4, 8, 12, 18, 24, and 28 
weeks.(65)   
 
STUDY SETTING 
Malawi is a landlocked country in southeast Africa that has one of the lowest gross domestic 
products per capita ($860 based on purchasing power parity), and one of the highest maternal and 
infant mortality rates (460 deaths per 100,000 live births and 79 deaths per 1,000 live births, 
respectively).(66, 67) Approximately 10.8% of adults aged 15-49 in Malawi are HIV-infected. More than 
90% of pregnant women attend at least one antenatal visit in Malawi, and HIV testing coverage within 
antenatal clinics in Lilongwe is greater than 90 percent.(68) Fifty-four percent of pregnant women have 
an institutional delivery with a skilled attendant and three percent receive a caesarean section.(68)  The 
vast majority of women (72%) exclusively breastfeed their infants in the first months of life and 77% of 
women continue breastfeeding for at least two years.(68)  
 
Lilongwe is the capital of Malawi, with a population of 670,000 people.(67) While Lilongwe is the 
most populous city in the country, it is still deemed peri-urban.  The study population should allow the 
results of this research to be generalized to other parts of Malawi, and potentially other countries with 
generalized HIV epidemics in sub-Saharan Africa. 
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SPECIFIC AIM 1 
Estimate the association between postnatal maternal and infant antiretroviral adherence and 
breastmilk HIV transmission between 5 and 38 weeks of life. 
 
Rationale:  Vertical HIV transmissions have occurred even in the setting of highly suppressive 
prophylaxis regimens.  One possible explanation for transmissions is poor antiretroviral adherence.  As 
extended PMTCT regimens that continue until complete cessation of breastfeeding and beyond are now 
promoted by WHO, it is imperative to know the relationship between adherence and HIV transmission 
during breastfeeding.   
 
Design:  We used an observational prospective cohort study to look at the relationship between 
adherence to the assigned prophylaxis regimen and breastmilk HIV transmission among all mothers and 
infants in the two treatment arms (maternal ARV and infant NVP).   
 
Study Population:  Our study population will consist of mother-infant pairs randomized to the 
two treatment arms of BAN, maternal ARV (n=849) and infant NVP (n=852). Mother-infant pairs that 
were randomized to the enhanced control arm of BAN (n=668) will be excluded because they were not 
exposed to the extended postnatal regimen.  Infants in the two treatment arms that were diagnosed as 
HIV-positive between birth and 4 weeks of age (n=86) were excluded, as we had no adherence measure 
prior to their becoming HIV-infected. Similarly, infants in the two treatment arms that were lost to 
follow-up (n=84) or died (n=6) before by 4 weeks of age were excluded.  In addition mother-infant pairs 
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with unknown breastfeeding status were excluded (n=46), as we could not ensure the infants were at 
risk of breastmilk HIV transmission. Our analysis thus included a total of 1479 mother-infant pairs.   
 
Exposure and Outcome Assessment: Our main exposure of interest was adherence to the 
prescribed postpartum antiretroviral prophylaxis regimen.  Adherence was measured at the following 
intervals using maternal ARV pill count and NVP suspension bottle weight from contiguous visits: 2-4 
weeks, 8-12 weeks, 13-18 weeks, and 24-28 weeks.  Adherence measures were not available for weeks 
5-7, and 19-23. For analysis purposes, the unobserved adherence during weeks 5-7 and weeks 19-23 
were assumed to be equal to the observed adherence during weeks 8-12 and weeks 24-28, respectively. 
Percent adherence was treated as a time-varying exposure, and calculated using the BAN dosing 
regimens and the following two formulae:   
 
Pill count: (# of pills distributed at previous visit - # of pills returned at current visit)  
                       (days between visits * pills prescribed per day) 
 
Bottle weight: (# of grams distributed at previous visit -  # of grams returned at current visit)  
                       (days between visits * grams prescribed per day)   
 
Adherence to each drug included in the maternal ARV regimen was calculated separately.  In 
that all three drugs contained in the ARV regimen need to be taken for the regimen to be complete, we 
used the percent adherence for the least adherent drug as the percent adherence for the ARV regimen 
at each visit.  Only NVP adherence was used for the infant NVP arm.  Percent adherence was coded in 
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the following ways:  continuous using any necessary transformations (e.g..: splines); dichotomous (> 
90% vs. < 90%, based on previous studies and expected distribution of our adherence data); and as data-
driven categories. We assessed the choice of cutoff for our dichotomous adherence measure in 
sensitivity analyses described below. 
 
Pill count and bottle weight adherence measures were compared to self-reported adherence. 
Self-reported adherence was measured at 4, 8, 21, and 28 weeks postpartum based on the mother’s 
answers to the following question: “During the past three days excluding today, have you/your baby 
missed any doses of (name of each individual antiretroviral prescribed)?” Self-reported adherence was 
considered a time-varying dichotomous variable (no reported missed doses of any drugs vs. at least one 
reported missed dose of any drug).  Dichotomous self-reported and dichotomous pill count or bottle 
weight adherence measures were compared. However, the two measures assess adherence over 
different time periods (pill count and bottle weight: an interval of 2-6 weeks, self-report: an interval of 3 
days) and were therefore expected to differ.  
 
Our main outcome was breastmilk HIV transmission, determined by Roche Amplicor 1.5 DNA 
PCR (Roche Molecular Systems, Pleasanton, CA, USA) at 2, 12,  28, and 48 weeks to indicate infant HIV 
status. PCR positive results were confirmed by testing an additional blood specimen, and the window of 
infection was narrowed with tests of infant dried blood-spot specimens taken at 4, 6, 8, 18, 24, 32, and 
36 weeks.  Breastmilk HIV transmission was treated as a dichotomous variable. PCR detected HIV in 
infant DBS specimens between 5 and 38 weeks of age were considered as having the outcome. The date 
of the first PCR positive test was considered as the time transmission occurred. The date of the last PCR 
negative test was used for infants that remained HIV-uninfected during the study period. The frequency 
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of DBS collection and a narrow window for time of infection provided us with more accurate allocation 
of person-time by HIV-status than previously reported studies. 
 
Covariates:  Covariates consisted of randomization assignment, demographic characteristics, 
and health status information (Table 3.1).  All covariates were measured at baseline as part of the BAN 
trial, with the exception of breastfeeding status that was assessed using standardized questionnaires 
administered regularly during BAN. Data for each covariate was obtained from the BAN database.    
 
 Data Management: Data management for BAN was supervised by the Biostatistical Support Unit 
(BSU) of the UNC Center for Health Promotion and Disease Prevention (HPDP Center). The BSU 
facilitated data management activities such as creating datasets, establishing database storage 
procedures, and archiving file backups. Statisticians at UNC and CDC, study investigators, and the BSU 
worked in collaboration on all data management activities.  
 
 Data collection forms (DCFs) were provided for each subject. Study documents did not include 
any names of study participants.  Instructions for DCF use, data collection, and DCF scanning into the 
computerized database were provided by the BSU.  Data collection form components were formatted 
for use through Teleform®, were optically scanned in Lilongwe via Teleform, and were uploaded to a 
database in Chapel Hill. Range checks were built into all choice option fields, and data verification was 
done on-screen. Teleform software has been used for two other large studies conducted by UNC, and is 
currently the method of data management used in studies run through the Department of Health 
Promotion and Disease Prevention.(65)  
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 Laboratory specimens contained only a coded number in order to maintain subject 
confidentiality. Unique patient identification numbers were created by the BSU, and were used to link 
patient specific laboratory and demographic data. All electronic files were password-protected; access 
to files was only granted to authorized study personnel. 
 
 Demographic information, adherence assessments, infant HIV status, etc. were collected on 
various BAN study forms and stored in SAS datasets.  Viral load data were stored in an Excel spreadsheet 
and imported into a SAS file.  All relevant SAS datasets for this study were merged and checked for data 
integrity.   
 
Specific Aim 1: Statistical Analysis 
 Descriptive Analysis:  Distributions of all exposure, outcome and covariate variables were 
assessed to identify any outliers or unexpected values.  Frequencies, means, and medians were also 
calculated for all variables. 
 
Modeling Approach:  Binomial regression models using generalized estimating equations (GEE) 
and an exchangeable correlation matrix were used to test whether or not adherence changed over time.  
A Cox model with time-varying covariates was used to estimate the hazard ratio for infant HIV infection 
by adherence status.  Use of the Cox model allowed us to take into account lost-to-follow-up, death, 
time-varying adherence, time-dependent breastfeeding status, and time-fixed confounders. The Cox 
model follows the below formula, where the log of the hazard at time t is equal to the log of the 
baseline hazard function at time t (h0(t)) plus the beta coefficients for both the time-varying exposure 
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(β1xi1(t)) and time-fixed confounders (β2xi2). The hazard ratio is obtained by exponentiating the beta 
coefficient for the exposure at time t (e (β1xi1(t))) holding all other variables constant.  
 
 log hi (t) = h0(t) + β1xi1(t) + β2xi2 
 
Effect Measure Modification:  Effect measure modification was assessed by comparing the 
hazard ratio estimates and 95% confidence intervals from models with and without an interaction term 
between adherence and the covariate of interest. Covariates that produced adjusted hazard ratio 
estimates that were different enough to be clinically or programmatically relevant were considered 
effect measure modifiers. Potential effect measure modifiers are listed in Table 3.1. 
 
Confounding:  A directed acyclic graph (DAG) was used to identify potential confounders and a 
minimally sufficient adjustment set. Given the limited number of outcomes, a more parsimonious model 
was generated by removal of potential confounders that had minimal effect on the hazard ratio 
estimate or precision. Potential confounders are listed in Table 3.1.  
 
Multivariable Associations:  A backward elimination model strategy was implemented in order 
to evaluate each covariate in the presence of other covariates, and to consider joint effects.  Covariates 
were sequentially removed from the full model individually and then replaced to allow for assessment of 
joint effects.  The change-in-estimate was calculated for each model with a single covariate removed 
(compared to the full model).  The covariate producing the smallest change-in-estimate was then 
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removed permanently and the process repeated.  The effect of removing a covariate on the precision of 
the hazard ratio estimate for the main exposure-outcome relationship was assessed by the confidence 
limit ratio (upper limit/lower limit).   
 
Sensitivity Analyses:  Three main sensitivity analyses were conducted. First, sensitivity analyses 
were conducted around a range of values for ARV adherence during the study period.  Specifically we 
conducted sensitivity analyses using the following: 1) a cutoff of 85% pill count and bottle weight 
adherence for our dichotomous main exposure variable; 2) a cutoff of 95% pill count and bottle weight 
adherence for our dichotomous main exposure variable; and 3) our self-reported adherence measure as 
our main exposure, instead of pill count/bottle weight.   
 
Second, we assessed the impact of adjustment for baseline maternal viral load, which was not 
included in the main regression analyses. Baseline maternal viral load information was not available for 
3 mother-infant pairs, including one mother-infant pair who experienced a HIV-1 transmission event. 
However, due to the known association between viral load and HIV transmission, we included log-
transformed baseline maternal viral load in both the imputation and analysis models as a sensitivity 
analysis. 
 
Differential detection of HIV using nucleic acid testing may occur in a setting of infant NVP 
versus maternal ARV exposure.  Under daily NVP drug pressure an infant may have very low levels of 
virus, resulting in a limited number of cells that are infected with HIV, and a delayed positive DNA assay 
result.  In order to account for this possibility, we conducted a sensitivity analysis and assumed 
transmission among infants in the infant NVP arm occurred at the time of the last HIV-negative test 
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before receiving an HIV-positive test, rather than assuming transmission occurred at the time of the first 
HIV-positive test.  
 
Missing Data:  Multiple imputation was used in order to account for missing adherence 
measures.(69)  Adherence was assumed to be missing at random. The probability of being adherent for 
each missing adherence measure was predicted from a fitted logistic regression model comprised of 
variables believed a priori to be predictive of adherence and for which there was minimal missing data. 
Covariates used to predict adherence included ARV study arm, maternal age (continuous), parity (0, >1), 
marital status, (married, not married), education status (<primary, >primary), baseline maternal CD4+ 
category (200-350, 351-500, >500), baseline maternal hemoglobin (<11mg, >11mg), previous visit(s) 
adherence, time-dependent breastfeeding status, infant’s outcome, and log survival time. Five hundred 
complete data sets were imputed based on the logistic regression predicted probabilities. Extended 
unadjusted and adjusted Cox models were then fit to obtain parameter and variance estimates for each 
of the 500 datasets, and these estimates were combined to obtain a final mean hazard ratio estimate 
and 95% confidence interval.(70)   
 
Tied data:  The number of transmissions was small, therefore tied event times (transmissions 
occurring at the same time) were not thought to be problematic. However, tied data were handled using 
the exact method in SAS which assumes time is continuous and that ties arise from grouping continuous, 
untied data.   
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All data analyses and power calculations were conducted using SAS version 9.2 and 9.3 (SAS 
Institute, Cary, North Carolina, USA) and Stata version 11 (StataCorp LP, College Station, Texas, USA). 
  
 Power Calculations: There were 12 (1.7%) and 21 (2.9%) infections that occurred between 2 and 
28 weeks in the NVP and ARV arms, respectively.  Low transmission rates lead us to assume that most 
women and infants were adherent to their prescribed regimen.  In addition, the desire to protect their 
infant from acquiring HIV is thought to provide high motivation for mothers to be adherent to their 
medication, and the administration of medication to their infant. High adherence motivation coupled 
with the close follow-up from a clinical trial is also thought to result in high rates of adherence.  We 
further assumed that the majority of transmissions that occurred were due to poor adherence to 
medication, and that a smaller proportion of transmissions occurred despite perfect adherence, 
potentially due to drug resistance or other biological mechanisms.  Specifically, we assumed adherence 
rates would be between 85-95% and that between 10-40% of transmissions would occur in the adherent 
group.  Based on these assumptions, we had over 80% power to detect hazard ratios between 3.7 (85% 
adherence; 40% transmissions in adherent group) and 15.0 (95% adherence; 10% transmissions in 
adherent group) for combined maternal and infant adherence (Figure 3.1).  
 
Limitations: We used pill count and bottle weight to categorize exposure status, which may lead 
to some misclassification of exposure. We were also reliant on the frequency with which mothers 
returned for visits and study staff collected complete adherence information. Missing pharmacy forms 
resulted in extended and inconsistent intervals between adherence measures, and an incomplete 
overall adherence estimation.  We used multiple imputation to account for missing adherence 
measures.   
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We were also limited by the relatively small number of transmissions that occurred in the two 
BAN treatment arms between 5-38 weeks postpartum (n=45), which prevented us from making 
comparisons of the association between adherence and transmission by study arm. In addition, 
unmeasured factors may have affected the relationship between adherence and transmission, biasing 
our observed associations.   
 
Alternative approaches: A randomized control trial that randomizes mothers or infants to sub-
optimal adherence would not be ethical. This research built upon an existing cohort of mother-infant 
pairs that were and were not adherent to their randomized prophylaxis regimen, and allowed us to 
answer the specific aim by means of an observational cohort study. 
 
SPECIFIC AIM 2 
Estimate the association between postpartum maternal antiretroviral adherence, plasma HIV viral 
load, breastmilk HIV viral load, and breastmilk HIV transmission between 2 and 28 weeks of life. 
 
Rationale:  Suboptimal adherence to prescribed antiretroviral prophylaxis regimens may affect 
the rate at which the antiretrovirals begin to suppress viral replication, and/or the duration of the effect 
on viral replication (pharmacokinetics), resulting in increased HIV viral load. Higher viral loads have been 
associated with higher risk of HIV transmission. This study allowed us to estimate the association 
between antiretroviral adherence, resulting plasma and breastmilk HIV viral load, and subsequent HIV 
infection. The effect of adherence on viral load and HIV transmission have important implications for 
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adherence counseling messages and determining the cost-effectiveness of routine viral load screening 
among HIV-positive breastfeeding mothers. 
 
 Design: We used a cost efficient case-cohort design to take into account plasma and breastmilk 
HIV viral load when assessing the association between adherence and breastmilk transmission of HIV.  
 
 Study Population:  We included all mother-infant pairs in the 28 weeks of triple maternal ARV or 
daily infant NVP arms with available plasma or breastmilk samples and an HIV transmission event 
between 2 and 28 weeks of the infant’s life (n=31). We also included a 15% sample of mother-infant 
pairs randomized to the two treatment arms of BAN where HIV transmission did not occur within 28 
weeks of life (n=232); sampling was primarily based on stored breastmilk and plasma availability. 
Mother-infant pairs who experienced transmission between birth and two weeks of age (n=86) were 
excluded and information on first-born multiples was used when multiple births occurred (n=5). Our 
analysis thus included a total of 263 mother-infant pairs at risk of breastmilk HIV transmission between 
2 and 28 weeks of age.  
 
 Exposure and Outcome Assessment:  Exposure and outcome varied by contrast estimated and 
included the following: 1) adherence (exposure) and plasma HIV VL (outcome), 2) adherence (exposure) 
and breastmilk HIV VL (outcome); 3) plasma HIV VL (exposure) and breastmilk HIV VL (outcome), and 4) 
breastmilk HIV VL (exposure) and breastmilk HIV transmission (outcome) (Table 3.2).  
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Maternal adherence was calculated for the following postpartum time intervals: 2-4 weeks, 8-12 
weeks, and 13-18 weeks. Adherence to triple maternal ARVs was calculated using pill counts taken by 
trained pharmacy staff on contiguous visits, and has been described in detail in Aim 1. Briefly, maternal 
ARV adherence was calculated from the difference in the number of pills distributed at the previous visit 
and the number returned at the current visit, compared with the number of pills that should have been 
taken between visits if the mother was perfectly compliant. Mothers randomized to the infant NVP arm 
were assigned a maternal adherence value of zero for all intervals. Maternal adherence was categorized 
into the following using disjoint indicator variables, 0-80% (“poor adherence”, referent), 81-98% 
(“partial adherence”), and >98% (“near perfect adherence”). Categories were chosen based on previous 
studies and the observed adherence distribution.(34)  
 
HIV RNA was quantified from blood plasma and whole breastmilk at enrollment, 2, 6, 12, 18, and 
24 weeks postpartum. In addition, breastmilk HIV RNA was measured at 4 and 8 weeks post-delivery. 
Plasma VL was quantified using the Abbott RealTime HIV assay (Abbott Molecular, Des Plaines, IL) and 
the 0.6ml protocol according to the package insert (lower limit of quantitation 40 copies/ml). Breastmilk 
VL was quantified from 0.6 ml whole breastmilk pre-treated with 209ul Abbott RNA sample prep lysis 
buffer and 60ul Abbott Proteinase K (53°C incubation for 20 min) using the Abbott RealTime HIV assay 
(Abbott Molecular, Des Plaines, IL; lower limit of quantitation 56 copies/ml). HIV RNA concentrations 
that were detected but below the limit of quantitation were assigned a value of 39 for plasma and 55 for 
breastmilk (lower limit of quantitation minus one), and RNA concentrations that were undetectable 
were assigned a value equal to 50% of the lower limit of quantitation (plasma: 20, breastmilk: 28). VL 
was then categorized as detectable (plasma: >40 copies/ml, breastmilk: >56 copies/ml) or undetectable 
 
 
28 
 
(plasma: <40 copies/ml, breastmilk: <56 copies/ml) when treated as a binary variable, and log10-
transformed when treated as a continuous variable. 
 
Infant HIV status was determined at 2, 12, 28, and 48 weeks by Roche Amplicor 1.5 DNA PCR 
(Roche Molecular Systems, Pleasanton, CA, USA). PCR positive results were confirmed by testing an 
additional blood specimen, and the window of infection was narrowed with tests of infant dried blood-
spot specimens taken at 4, 6, 8, 18, 24, and 32 weeks. Breastmilk transmission was defined as first 
detection of HIV infection by PCR in infant blood between 2 and 28 weeks of age, and treated as a 
dichotomous variable. Covariates included randomization assignment, demographic characteristics, and 
health status as described in Aim 1 (Table 3.1). 
 
Covariates:  Covariates consisted of randomization assignment, demographic characteristics, 
and health status information (Table 3.1).  All covariates were measured at baseline as part of the BAN 
trial, with the exception of breastfeeding status that was assessed using standardized questionnaires 
administered regularly during BAN. Data for each covariate was obtained from the BAN database.    
 
Specific Aim 2: Statistical Analysis 
 
Descriptive Analysis and Weighting Structure:  Descriptive analyses were conducted as described 
in Aim 1. Sampling weights were used to take into account the sampling of cases and non-cases, 
realizing that the sampled cases and non-cases represent a larger population. Specifically, the reciprocal 
of the study inclusion probability was used as a sampling weight in all regression analyses.   
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General Modeling Approach: We used generalized linear mixed models with identity link and 
Gaussian distribution to estimate the difference in log10 plasma VL by adherence category, and logit link 
with binomial distribution to estimate odds ratios for detectable breastmilk VL by adherence and plasma 
VL category. Single and multivariable Cox models were used to estimate the hazard ratio for the rate of 
breastmilk HIV transmission by 28 weeks of age. Mother-infant pairs were censored at reported 
cessation of breastfeeding unless HIV transmission occurred within 30 days of reported cessation, and 
mother-infant pairs that were lost to follow-up were censored at the time of their last PCR negative HIV 
test.(71)  
 
Effect Measure Modification:  Effect measure modification was assessed by comparing model-
specific effect estimates (i.e. beta coefficients, odds ratios, and hazard ratios) and 95% confidence 
intervals from models with and without an interaction term between the exposure and covariate of 
interest. Covariates that produced adjusted estimates that were different enough to be clinically or 
programmatically relevant were considered effect measure modifiers. Potential effect measure 
modifiers are listed in Table 3.1. 
 
Confounding:  Confounding was assessed by using a DAG, identifying a minimally sufficient 
adjustment set, and then using a backward elimination approach as described in Aim 1. However, the 
effect estimates for Aim 2 included beta coefficients, odds ratios and hazard ratios. Potential 
confounders are listed in Table 3.1. 
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Multivariable Associations:  A backward elimination model strategy was implemented as 
described in Aim 1.  However, the effect estimates for Aim 2 included beta coefficients, odds ratios and 
hazard ratios. 
 
Missing Data:  Missing adherence, plasma VL, and breastmilk VL measures were multiply 
imputed using proc mi in SAS. Dichotomous variables were imputed using logistic regression, and 
continuous variables were imputed using predictive mean matching. 
 
Power Calculations: Our sample size was fixed, as it utilized laboratory results from an existing 
protocol (PI: Susan Fiscus). Power for all sub-aims was based on 33 cases (all HIV-infected infants in ARV 
intervention arms) and 158 non-cases (10% of the HIV-uninfected infants), and is described in detail 
below. Power calculations used exact methods due to the small sample size.  An alpha level of 0.05 was 
used for all power calculations.  Power may slightly decrease after adjusting for necessary covariates, 
but this study had sufficient power to detect meaningful comparisons in the differences in viral load and 
risk of HIV transmission by adherence category. 
 
 As in Aim 1 we assumed that most mothers and infants would adhere to their prescribed drug 
regimen, and therefore only a minority would have a detectable HIV RNA viral load in plasma and 
breastmilk.  We also assumed that the majority of those with a detectable viral load would be in the 
non-adherent group, while realizing that a small proportion of those that are adherent may still have a 
detectable viral load due to factors such as drug resistance. We used a conservative estimate of power 
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and present the minimum power that would be expected, as it assumed only one sample would be used 
per subject. However, power was expected to increase due to the use of repeated measures.  
 
 We had 84% power to detect an odds ratio of 0.15 assuming 85% adherence and that 70% of 
those in the non-adherent group would have a detectable viral load (Table 3.3).  We thought it 
reasonable to assume that there is a large association between adherence and viral load, and therefore 
anticipated the odds ratios outlined in Table 3.3.  
 
 Similarly, we assumed that the vast majority of transmissions would occur in subjects with a 
detectable viral load.  We had over 80% power to detect a hazard ratio of 2.4 assuming 30% would have 
a detectable viral load and 20% of those with an undetectable viral load would result in a transmission 
event (Table 3.4).  We thought it reasonable to assume that there is a large association between viral 
load and resulting transmission, and therefore anticipated fairly large hazard ratios.  
 
All data analyses and power calculations were conducted using SAS version 9.2 and 9.3 (SAS 
Institute, Cary, North Carolina, USA), and Stata version 11 (StataCorp LP, College Station, Texas, USA). 
 
Limitations: Potential limitations regarding our adherence measure and unmeasured factors are 
as described in Aim 1. Another limitation was a lack of plasma or breastmilk samples at the selected 
time points, which introduced large gaps in timelines. We were dependent on the frequency with which 
mothers returned for visits and study staff collected blood and breastmilk specimens at each visit. 
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Specimens were collected and stored more frequently than in other PMTCT studies, making this less of a 
problem than in studies where specimens were collected much less often.   
 
Due to the small number of transmissions that occurred in the BAN trial we combined data from 
the maternal ARV and infant NVP arm.  While it would be ideal to look at the effects of adherence to 
maternal ARV and infant NVP separately, we were not powered to study such differences.   
 
We did not have HIV DNA viral loads for breastmilk specimens. Maternal ARV adherers may 
have suppressed breastmilk HIV RNA but had persistent breastmilk HIV DNA, potentially explaining 
transmissions that occurred despite perfect adherence.  In addition, if compartmentalization or local 
viral evolution was occurring within the breast, then transmission may have resulted despite perfect 
adherence due to viral replication or evolution taking place where only 3TC and ZDV have been shown 
to concentrate.(72)  Inflammation in the breast and/or drug resistance may have also contributed to 
transmission, but was not included in this study.  Future work is being planned by Sabrina Zadrozny and 
Julie Nelson to examine the role that mastitis and resistance play in transmission, respectively. We took 
all of these limitations into account when generating conclusions about the relationships examined in 
this study. 
 
 Alternative approaches: A cohort design would have been optimal to look at the effects of 
plasma and breastmilk HIV viral load on the association between adherence and transmission; however, 
such a design would be extremely costly.  Use of a case-cohort design allowed us to achieve Aim 2 in a 
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cost-efficient and timely manner, while maintaining enough power to detect meaningful and significant 
differences.    
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Table 3.1. Potential effect measure modifiers or confounders for all aims.* 
Covariate Definition and coding 
ARV randomization Categorical: maternal ARVs not including 
lopinavir/ritonavir, maternal ARVs including 
lopinavir/ritonavir, infant NVP 
Nutritional randomization Dichotomous:  nutritional supplement (=1) vs. no 
supplement (=0) 
Mothers:  
     Age Age in years, continuous† 
     Parity Continuous† 
     Marital status Categorical: married/cohabitating, 
divorced/separated/never married, widowed 
     Education Dichotomous: < primary school (=1) vs.  
> primary school (=0) 
     Baseline CD4 count Count per mm3, continuous† 
     Serious adverse events Dichotomous: > 1 (=1) vs. none (=0) 
     ARV regimen Categorical:  ZDV/3TC/NVP, ZDV/3TC/NFV, 
ZDV/3TC/LPV/r 
Infants:  
     Sex Dichotomous:  male (=1) vs. female (=0) 
     Birth weight Weight in kilograms, continuous† 
     Age Age in months, continuous† 
     Serious Adverse events Dichotomous: > 1 (=1) vs. none (=0) 
*Parameters were decided based on expert knowledge and use of a causal diagram 
†Continuous variables may be re-coded as categorical variables for analyses. 
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Figure 3.1. Power curve for Aim 1; maternal ARV and infant NVP arms combined  
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Table 3.2. Summary of contrasts evaluated in Aims 1 and 2 
Aim Exposure 
Exposure 
Structure 
Outcome 
Outcome 
Structure 
Proposed 
Model 
1 Adherence 
Continuous, 
Categorical, 
Dichotomous 
HIV 
Transmission 
Dichotomous Cox model 
            
2.1  Adherence 
Continuous, 
Categorical, 
Dichotomous 
Viral Load 
Continuous, 
Dichotomous 
Mixed effects 
models 
            
2.2 Viral Load 
Continuous, 
Categorical, 
Dichotomous 
HIV 
Transmission 
Continuous, 
Dichotomous 
Cox model 
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Table 3.3. Aim 2 assumptions and power calculations for the association  
between adherence and viral load 
% adherence % detectable VL among 
non-adherent group 
% Power Odds Ratio 
85 50 74 0.15 
85 70 84 0.15 
85 90 89 0.10 
90 50 66 0.10 
90 70 81 0.10 
90 90 95 0.05 
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Table 3.4. Aim 2 assumptions and power calculations for the association 
 between viral load and HIV transmission 
% detectable 
viral load 
% transmissions in 
undetectable VL group 
% Power Hazard 
Ratio 
20 15 81 2.8 
20 20 84 2.6 
30 15 87 2.8 
30 20 83 2.4 
40 15 82 2.6 
40 20 81 2.3 
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CHAPTER FOUR: SPECIFIC AIM 1 RESULTS  
ADHERENCE TO EXTENDED POSTPARTUM ANTIRETROVIRALS IS ASSOCIATED WITH DECREASED 
BREASTMILK HIV-1 TRANSMISSION 
 
INTRODUCTION 
The World Health Organization (WHO) now recommends that all pregnant and breastfeeding 
women with HIV infection receive lifelong antiretroviral therapy (ART) in an effort to simplify and 
standardize prevention of mother-to-child HIV transmission (PMTCT) prophylaxis regimens, and achieve 
global goals of eliminating new infant HIV infections and keeping their mothers alive.(32) Effective 
implementation of this WHO guidance relies on adherence to the prescribed antiretroviral regimen.(14) 
Maintaining adherence to antiretroviral (ARV) prophylaxis regimens has been challenging for patients, 
and predicting who will be non-adherent and intervening in an effective way has been challenging for 
PMTCT programs.(54, 61-64, 73) During the postpartum period, almost one half of patients included in a 
recent meta-analysis did not maintain an adherence level thought to be needed for virological 
suppression (>80%).(48)   
 
Non-adherence to ART and PMTCT regimens may occur for several reasons, including: time and 
financial costs of accessing care, stigma, forgetfulness or changes in routine, and side effects of 
medications.(43, 49-54) Among adults who are not pregnant or breastfeeding, greater than 95% 
adherence is thought to be needed to maintain virological suppression when unboosted protease 
inhibitors (PI) are included in the ART regimen.(35) Pharmacokinetic boosting of PIs with drugs such as 
ritonavir has been used to extend the plasma half-life of the active PI by inhibiting drug metabolism.(36, 
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37) With boosted PIs, 80% adherence may be sufficient for adults who are not pregnant or 
breastfeeding to achieve virological suppression.(38-40) To our knowledge this is the first study to assess 
the level of adherence needed for postpartum maternal ARV regimens or extended infant nevirapine 
(NVP) to prevent breastmilk HIV transmission. 
 
Despite the efficacy of ART in PMTCT, transmission does occur even in the context of closely 
monitored clinical trials for poorly understood reasons.(4, 5, 7, 8, 74) In this paper, we use data from a 
recent randomized PMTCT trial in Malawi to: 1) estimate adherence to a postpartum maternal triple 
antiretroviral regimen and daily infant NVP using pill counts, bottle weights, and maternal self-report; 2) 
compare the characteristics of mother-infant pairs by adherence category; and 3) quantify the effect of 
adherence to both a maternal triple antiretroviral regimen and extended daily infant NVP on breastmilk 
HIV transmission.   
 
METHODS 
The Breastfeeding, Antiretrovirals and Nutrition (BAN) trial was conducted in Malawi between 
2004 and 2010 using a factorial design to assess the benefit and safety of antiretroviral medications 
given either to infants or to their mothers to prevent HIV transmission during breastfeeding.(7) Mothers 
were recruited at antenatal clinics in Lilongwe, where HIV testing was conducted. Eligibility criteria for 
mother-infant pairs included the following: antibody-confirmed maternal HIV infection, maternal CD4 
>250 cells/µL (>200 cells/µL before July 24, 2006), no previous antiretroviral drug use (including single 
dose NVP), infant birth weight of at least 2000 grams, no infant or maternal condition that would 
preclude the use of a study drug, and able to be enrolled within 36 hours of delivery.(7)   
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All mothers and infants enrolled in BAN received one dose of NVP and seven days of zidovudine and 
lamivudine postpartum.(7) In addition, mother-infant pairs were randomized to receive one of the 
following postpartum PMTCT prophylaxis regimens: 1) 28 weeks of a maternal triple antiretroviral 
regimen (maternal ARV); 2) 28 weeks of infant NVP; or 3) no further drugs postpartum (enhanced 
control).(7) Mothers were also randomized to either receive or not receive a nutritional intervention 
consisting of a lipid-based nutrient supplement throughout breastfeeding.(7) All mothers were advised 
to breastfeed exclusively for the first 24 weeks postpartum with weaning between 24 and 28 weeks.(7) 
Details of the drug regimens and nutrition supplement have been reported previously.(71, 75, 76)   
 
Study design 
The study population consisted of mother-infant pairs randomized to the two treatment arms of 
BAN, maternal ARV (n=849) and infant NVP (n=852). We excluded mother-infant pairs that were not 
randomized to an extended postnatal antiretroviral regimen (n=668), and infants who had one of the 
following outcomes between birth and four weeks of age: HIV infection (n=86), death (n=6), lost to 
follow-up (n=84), or unknown breastfeeding status (n=46) (rationale described in more detail below). 
Information on first-born multiples was used when multiple births occurred (n=31). Our analysis thus 
included a total of 1479 mother-infant pairs at risk of breastmilk HIV transmission between 5 and 38 
weeks of age.  
 
Data analyses 
Breastmilk HIV transmission was determined by Roche Amplicor 1.5 DNA PCR (Roche Molecular 
Systems, Pleasanton, CA, USA) at 2, 12,  28, and 48 weeks to indicate infant HIV status. PCR positive 
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results were confirmed by testing an additional blood specimen, and the window of infection was 
narrowed with tests of infant dried blood-spot specimens taken at 4, 6, 8, 18, 24, 32, and 36 weeks. The 
primary outcome was breastmilk transmission, defined as first detection of HIV infection by PCR in 
infant blood between 5 and 38 weeks of age, and treated as a dichotomous variable. The secondary 
outcome was time until either first detection of infant HIV infection or infant death by 38 weeks. The 
process for death ascertainment has been described previously.(71)  
 
The main exposure of interest was adherence to the prescribed postpartum ARV regimen. We 
measured adherence two ways: 1) maternal ARV pill counts or infant NVP suspension bottle weights, 
taken by trained pharmacy staff (hereafter referred to simply as “adherence”); and 2) maternal self-
report, using a standardized questionnaire (used in sensitivity analyses, hereafter referred to as “self-
reported adherence”). Only pill counts and bottle weights measured on contiguous visits were used, and 
included visits at the following weeks of infant age: 2, 4, 8, 12, 18, 24, and 28. Adherence was then 
calculated for the following time intervals: 2-4 weeks, 8-12 weeks, 13-18 weeks, and 24-28 weeks of age. 
Adherence measures were not available for weeks 5-7, and 19-23. For analysis purposes, the 
unobserved adherence during weeks 5-7 and weeks 19-23 were assumed to be equal to the observed 
adherence during weeks 8-12 and weeks 24-28, respectively.  Adherence was calculated using BAN 
dosing regimens (71) and the following two formulae.  
 
 Pill count: (# of pills distributed at previous visit - # of pills returned at current visit)  
                               (days between visits * pills prescribed per day) 
Bottle weight: (# of grams distributed at previous visit -  # of grams returned at current visit)  
                                  (days between visits * grams prescribed per day)   
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If adherence was outside of the 0 or 1 bounds, we truncated it to 0 or 1, respectively. Because 
all three prescribed ARV drugs are necessary for full regimen activity, we made separate calculations for 
each drug and used the lowest percentage of the three to define a patient’s ARV adherence at a given 
interval. A cutoff of 90% was then used to dichotomize adherence (<90% adherent=non-adherent; >90% 
adherent=adherent). The choice of adherence cutoff was based on previous studies and the expected 
adherence distribution.(34)  
 
Self-reported adherence was measured at 4, 8, 21, and 28 weeks postpartum and based on the 
mother’s answer to the following question: “During the past three days excluding today, have you/your 
baby missed any doses of (name of each individual antiretroviral prescribed)?” Self-reported adherence 
was considered a time-varying dichotomous variable (>1 reported missed dose of any drug; no reported 
missed doses of any drugs).    
 
Potential confounding variables consisted of randomization assignment, demographic 
characteristics, and health status information (Table 4.1). All covariates were measured at baseline as 
part of the BAN trial. Frequencies, means, and medians were also calculated, as appropriate, to compare 
characteristics of mother-infant pairs by exposure (adherence) and outcome (HIV status) category. 
Binomial regression models using generalized estimating equations (GEE) and an exchangeable 
correlation matrix were used to test whether or not adherence changed over time.   
 
A Cox model was used to assess the association between adherence and the rate of breastmilk 
HIV transmission and breastmilk HIV transmission or infant death by 38 weeks of age, adjusting for 
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potential prognostic factors. Adherence was included in the Cox model as a time varying covariate, 
lagged by one interval to ensure the exposure occurred prior to the outcome. Mother-infant pairs lost to 
follow-up were censored at the time of their last PCR negative HIV test.  
 
Effect measure modification was assessed by comparing unadjusted and adjusted hazard ratio 
estimates and 95% confidence intervals using an interaction term between adherence and the variable 
of interest. Covariates that produced adjusted hazard ratio estimates that were different enough to be 
clinically or programmatically relevant were considered effect measure modifiers. A directed acyclic 
graph (DAG) was used to identify potential confounders and a minimally sufficient adjustment set.(77) 
Given the limited number of outcomes, a more parsimonious model was generated by removal of 
potential confounders that had minimal effect on the hazard ratio estimate or precision. 
 
Multiple imputation was used in order to account for missing adherence measures.(69).  
Adherence was assumed to be missing at random. The probability of being adherent for each missing 
adherence measure was predicted from a fitted logistic regression model comprised of variables 
believed a priori to be predictive of adherence and for which there was minimal missing data. Covariates 
used to predict adherence included ARV study arm, maternal age (continuous), parity (0, >1), marital 
status, (married, not married), education status (<primary, >primary), baseline maternal CD4+ category 
(200-350, 351-500, >500), baseline maternal hemoglobin (<11mg, >11mg), previous visit(s) adherence, 
time-dependent breastfeeding status, infant’s outcome, and log survival time. Five hundred complete 
data sets were imputed based on the logistic regression predicted probabilities. Extended unadjusted 
and adjusted Cox models were then fit to obtain parameter and variance estimates for each of the 500 
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datasets, and these estimates were combined to obtain a final mean hazard ratio estimate and 95% 
confidence interval.(70)   
 
Three sensitivity analyses were conducted to address self-reported adherence, baseline 
maternal viral load, and timing of infant HIV infection. First, we compared self-reported adherence with 
pill count and bottle weight adherence, and compared the association between adherence and 
breastmilk HIV transmission using each adherence measurement method. To do this, self-reported 
adherence was considered as the main exposure in sensitivity analyses, instead of adherence measured 
by pill count or bottle weight. Second, we assessed the impact of adjustment for baseline maternal viral 
load, which was not included in the main regression analyses. Baseline maternal viral load information 
was not available for 3 mother-infant pairs, including one mother-infant pair who experienced a HIV 
transmission event. However, due to the known association between viral load and HIV transmission, 
we included log-transformed baseline maternal viral load in both the imputation and analysis models as 
a sensitivity analysis. Third, we assessed potential measurement error associated with assignment of 
transmission timing due to the use of daily infant NVP. In a setting of infant NVP versus maternal ARV 
exposure, differential detection of HIV using nucleic acid testing may occur. Under daily NVP drug 
pressure an infant may have very low levels of virus, resulting in a limited number of cells that are 
infected with HIV, and a delayed positive DNA assay result. In a sensitivity analysis, transmission was 
assumed to occur at the time of the last HIV-negative test rather than the time of the first HIV-positive 
test for infants in the infant NVP arm. All data analyses were conducted using SAS version 9.3 (SAS 
Institute, Cary, North Carolina, USA). 
 
 
 
46 
 
RESULTS 
A total of 1479 mother-infant pairs were included in analyses (Figure 4.1). The median maternal 
age was 26 years [interquartile range (IQR): 23 to 29]. Most mothers were married (93%) and reported 
at least one previous live birth (87%) (Table 4.1). Among those randomized to the maternal ARV arm, 
most received a boosted protease inhibitor regimen of zidovudine, lamivudine, and lopinavir-ritonavir 
(79%) (Table 4.1). Mothers had a median baseline CD4+ count of 477 per uL (IQR: 330 to 582), a median 
baseline log10 viral load of 4.1 copies per milliliter of blood (IQR: 3.6 to 4.7), and a median hemoglobin 
of 10.8 grams per dL (IQR: 10.0 to 11.7). The median infant birth weight was 3.0 kg (IQR: 2.7 to 3.3).  
 
Overall, mean pill count or bottle weight adherence was 87% [median 0.98; IQR: 0.82 to 1.00], 
and did not meaningfully differ by study arm (maternal arm 87%, infant arm 86%). Adherence changed 
over time in both the maternal and infant arm (p<0.001), but no consistent pattern was identified (Table 
4.2).  
 
Among all mother-infant pairs with at least one pill count or bottle weight adherence measure, 
22-40% were <90% adherent at any given interval (maternal ARV arm 24-42%, infant NVP arm 17-51%) 
(Table 4.2). A larger proportion of mother-infant pairs with a HIV transmission event were <90% 
adherent (41%) during any given interval compared with mother-infant pairs whose infants remained 
HIV-uninfected (33%) (Table 4.2), but the difference was not statistically significant (p=0.1).   
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Complete case 
A total of 501 mother-infant pairs had complete pill count or bottle weight adherence 
information (complete cases). Of these, 146 (29%) were always >90% adherent and 35 (7%) were never 
>90% adherent (Table 4.3).  
 
Among complete cases, 23 experienced a breastmilk HIV transmission event by 38 weeks of age 
(maternal ARV arm: 18, infant NVP arm: 5), and 28 experienced the composite outcome of breastmilk 
HIV transmission or infant death by 38 weeks (maternal ARV arm: 21, infant NVP arm: 7). Having >90% 
adherence was associated with a 60% relative reduction in the rate of breastmilk HIV transmission by 38 
weeks of age among complete cases, compared with having <90% adherence (Hazard Ratio (HR) 0.40; 
95% confidence interval (CI) 0.17-0.91) (Table 4.4). Adjustment for maternal age, baseline maternal 
CD4+ count, baseline maternal hemoglobin level, time-dependent breastfeeding status, and study arm 
had little impact (HR 0.41, 95% CI 0.18-0.94) (Table 4.4).  
 
Multiple imputation 
Adherence measured by pill count and bottle weight was imputed for 29% (431/1479) of 
mother-infant pairs at 4 weeks, 27% (387/1411) at 12 weeks, 29% (401/1375) at 18 weeks, and 43% 
(560/1310) at 28 weeks. No variables were significant predictors of adherence at all time points. 
 
Having >90% pill count or bottle weight adherence was associated with a 50% relative reduction 
in the rate of breastmilk HIV transmission by 38 weeks of age, compared with having <90% adherence 
[unadjusted HR 0.50, 95% CI 0.25-0.99] when using multiply imputed data (Table 4.4). The estimated 
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hazard ratio was similar when unadjusted Cox models were fit separately for each study arm [maternal 
ARV HR 0.51, 95% CI 0.21-1.21; infant NVP HR 0.48, 95% CI 0.16-1.44) (Table 4.4). Adjustment for 
potential confounding did not meaningfully change the hazard ratio estimate (HR 0.48; 95% CI 0.24-
0.97) (Table 4.4).  
 
Composite outcome: breastmilk HIV transmission or infant death 
Associations between adherence and the composite outcome of breastmilk HIV transmission or 
death did not appreciably differ from those using only HIV-transmission as the outcome (unadjusted HR 
0.58, 95% CI 0.32-1.04; adjusted HR 0.59, 95% CI 0.33-1.06).  
 
Sensitivity analyses 
A total of 541 mother-infant pairs had complete self-reported adherence information. Of these, 
22 experienced a breastmilk HIV transmission event (maternal ARV arm: 16, infant NVP arm: 6). Overall, 
92% of mothers self-reported missing no pills in the last three days. Self-reported adherence was similar 
by study arm (infant NVP: 0.93, maternal ARV: 0.90). Among complete cases, reporting missing no pills 
in the prior 3 days (100% self-reported adherence) was associated with a 74% relative reduction in the 
rate of breastmilk HIV transmission, compared with those self-reporting <100% adherence during the 
last three days (HR 0.26, 95% CI: 0.09, 0.71) and after adjusting for study arm, time-dependent 
breastfeeding status, and baseline maternal age, CD4+ count, and hemoglobin. The association 
remained similar when using multiply imputed self-reported adherence (n=1479, adjusted HR 0.33, 95% 
CI: 0.14, 0.78). 
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In the remaining two sensitivity analyses, minimal changes were observed. Including baseline 
maternal viral load in the imputation and analysis model resulted in a nearly identical association 
between pill count or bottle weight adherence and the rate of breastmilk HIV transmission (complete 
case HR 0.40, 95% CI 0.18-0.92; imputed HR 0.49, 95% CI 0.25-0.97), compared to models that did not 
adjust for baseline maternal viral load. Similarly, allowing for potential differential detection of HIV in an 
environment of maternal ARV versus daily infant NVP did not change the association between 
adherence and breastmilk HIV transmission (adjusted HR 0.43, 95% CI 0.19-1.01). 
 
DISCUSSION 
We have shown that adherence to antiretroviral regimens needs to be maintained throughout 
the breastfeeding period to maximize efforts to prevent breastmilk HIV transmission and improve infant 
HIV-free survival. To our knowledge, this study was the first in a resource-limited setting that assessed 
adherence over time to an extended postpartum prophylaxis regimen using pill count, bottle weight, 
and maternal self-report. The extent of missing adherence data in our study underscores the difficulty in 
consistently assessing adherence to postpartum antiretroviral medications, even in a well-monitored 
clinical trial with intensive follow-up.  
 
Non-adherence to ART has been associated with higher HIV viral loads in pregnant women, and 
compliance to short-course maternal zidovudine has been associated with decreased HIV vertical 
transmission.(41-43) Maternal ARV adherence rates had a negative but not statistically significant 
correlation with MTCT rates in a recent meta-analysis.(48) However, most studies in the meta-analysis 
used short-course ARV regimens and reported only antepartum adherence.(48) In contrast, we 
measured postpartum adherence over four time intervals, and allowed adherence to vary over time. In 
 
 
50 
 
addition, we used methods that account for missing adherence measures, infants lost to follow-up, and 
infant death.  
 
The number of transmission events was relatively small, despite the large sample size. The 
limited number of transmission events reduced the precision of our estimates, and prevented 
comparisons by study arm. We still observed a substantial effect of adherence on breastmilk HIV 
transmission, despite the small number of transmission events.  
 
Adherence levels found in BAN are similar to reported adherence from other randomized 
controlled trials of either extended infant or maternal antiretroviral prophylaxis during breastfeeding, 
and to a pooled postpartum adherence estimate.(4, 8, 9, 48, 74) However, direct adherence 
comparisons are difficult due to differences in the definition and measurement of adherence across 
trials. Adherence may be measured using a variety of approaches ranging in sophistication, but all are 
imperfect.(46) Self-reported adherence has the most potential for bias (usually in the form of 
overestimating adherence) due to recall and social desirability bias, but is the measurement tool most 
often used because it is easy and inexpensive to administer.(46) Adherence measurements based on pill 
count and suspension bottle weight are subject to manipulation, but are thought to have greater validity 
and take into account adherence over the entire monitoring period, rather than just the three days prior 
to the self-report assessment visit.(47) In our study, self-reported adherence was higher than adherence 
measured by pill count and bottle weight. However, both adherence measures resulted in a consistent 
association with breastmilk HIV transmission, increasing the confidence in our findings. 
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We attempted to determine an adherence threshold for transmission prevention. We assessed 
multiple adherence cutoffs (e.g.: 80% and 95%) and imputed adherence as a continuous measure. 
However, we were unable to identify an adherence threshold. Our findings suggest that the association 
between adherence and transmission is a continuum, with higher adherence leading to higher 
protection against transmission (results not shown).  
 
When adherence data are skewed, presenting only one measure of central tendency (e.g., mean 
or median) may fail to convey the characteristics of the adherence distribution, and be misleading. For 
example, median adherence in our study was 98%, suggesting that no further action is needed to 
maintain high levels of postpartum adherence.  Mean adherence was 87%, suggesting that some work is 
needed to improve adherence, but adherence remained high. In contrast, 22-40% of mother-infant pairs 
in our study were <90% adherent during each interval, suggesting that increased focus is needed to 
improve postpartum adherence. Variation in measures implies that some mother-infant pairs had very 
low adherence, and that some had intermittent non-adherence. Given that transmission is associated 
with non-adherence, there is a need to consistently emphasize adherence throughout the postpartum 
period. 
 
Non-adherence, however, did not account for all transmission events. Transmission may have 
occurred despite perfect adherence due to imperfection in our adherence measure, the length of time 
between maternal initiation of antiretrovirals and virological suppression, antiretroviral drug resistance, 
or other unidentified processes. Antiretroviral resistance testing could reveal whether resistance played 
a role in transmission events that occurred among adherent mother-infant pairs, and could also indicate 
non-compliance in the maternal ARV arm. The number of visits that could be used to assess adherence 
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resulted in inconsistent and extended time intervals between adherence measures. Adherence was held 
constant during the interval, and lagged to ensure the exposure occurred before the outcome. 
Therefore, measured adherence may not be the true adherence in the period immediately before 
transmission.  
 
Our results reinforce the need to focus on maintaining adherence to meet PMTCT goals. 
Furthermore, the extent of non-adherence in this heavily monitored clinical trial setting has important 
implications for adherence counseling messages, antiretroviral resistance concerns, local PMTCT 
program planning efforts, and global modeling exercises predicting MTCT elimination. We measured 
adherence through 28 weeks postpartum. However, WHO guidelines now recommend lifelong maternal 
ART for all HIV-positive pregnant and breastfeeding women.(32) Assessment of adherence and 
adherence-related outcomes throughout one to two years of breastfeeding is urgently needed.  
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Figure 4.1. Study population and outcomes  
 
  
 
1701 mother-infant pairs randomized to  
extended postpartum ARV regimen 
849 to Maternal Regimen 
852 to Infant NVP Regimen 
 
   222 were excluded 
86 infants HIV-infected <4 weeks of age 
  6 infants died <4 weeks of age  
84 infants lost to follow-up  <4 weeks of age 
46 infants had unknown breastfeeding status 
 
1479 mother-infant pairs included 
 
725 assigned to maternal ARV regimen 
   23 infants HIV-infected at 5-38 weeks 
   11 infants died at 5-38 weeks (2 HIV infected)  
   62 infants lost to follow-up at 5-28 weeks 
   
 
754 assigned to infant NVP regimen 
   22 infants HIV-infected at 5-38 weeks 
   12 infants died at 5-38 weeks (2 HIV infected) 
   62 infants lost to follow-up at 5-28 weeks 
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Table 4.1. Baseline characteristics of 1479 mother-infant pairs. 
   
  
Total* 
 (N=1479) 
HIV-1 infected 
infant** 
(N=45) 
HIV-1 uninfected 
infant† 
(N=1434) 
 
N 
 
(%) N 
 
(%) N 
 
(%) 
Antiretroviral randomization 
              Maternal antiretroviral 725
 
(49) 23
 
(51) 702
 
(49) 
     Infant nevirapine 754 
 
(51) 22 
 
(49) 732 
 
(51) 
Nutritional randomization 
     
         No supplement 733 
 
(50) 17 
 
(38) 716
 
(50) 
     Received supplement 746 
 
(50) 28 
 
(62) 718 
 
(50) 
Mothers: 
     
    Age (years) 
     
         15-25 720 
 
(49) 30 
 
(67) 690
 
(48) 
     26-35 680 
 
(46) 14 
 
(31) 666 
 
(47) 
     36-45 76 
 
(5) 1 
 
(2) 75 
 
(5) 
Education 
     
         Primary school only 941 
 
(64) 29 
 
(64) 912
 
(64) 
     > primary school 536 
 
(36) 16 
 
(36) 520 
 
(36) 
Married 
     
         No 110 
 
(7) 5 
 
(11) 105
 
(7) 
     Yes 1369 
 
(93) 40 
 
(89) 1329 
 
(93) 
Parity 
     
         0 193 
 
(13) 8 
 
(18) 185
 
(13) 
     >1 1280 
 
(87) 37 
 
(82) 1243 
 
(87) 
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Total* 
HIV-1 infected 
infant** 
HIV-1 uninfected 
infant† 
    N  (%)      N  (%)         N  (%) 
CD4+ count per mm3          
     200-350 450  (30) 20  (44) 430  (30) 
     351-500 478  (32) 13  (29) 465  (32) 
     >500 551  (37) 12  (27) 539  (38) 
Plasma viral load copies/mL          
    <1,000 147  (10) 1  (2) 146  (10) 
    1,001-10,000 425  (29) 7  (16) 418  (29) 
    >10,000 904  (61) 36  (82) 868  (61) 
Hemoglobin (g/dl)          
     <11  783  (53) 35  (78) 748  (52) 
     >11 696  (47) 10  (22) 686  (48) 
ARV Regimen‡          
     Nevirapine based 20  (3) 0  (0) 20  (3) 
     Nelfinavir based 124  (18) 5  (22) 119  (18) 
     Lopinavir/ritonavir based 556  (79) 18  (78) 538  (79) 
Infants          
Sex          
     Female 752  (51) 23  (51) 729  (51) 
     Male 727  (49 22  (49) 705  (49) 
Birth weight (kg)          
     <2.5 106  (7) 7  (16) 99  (7) 
     >2.5 1370   (93) 38   (84) 1332  (93) 
* Maternal plasma viral load not available for 3 mothers, ARV regimen not available for 25 mothers randomized to 
maternal ARV arm, and infant birth weight not available for 3 infants 
** Infant tested PCR positive for HIV-1 between 5 and 38 weeks of age  
† Includes 16 infants that tested PCR positive for HIV-1 after 38 weeks of age 
‡  Among those randomized to maternal ARV arm.  
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Table 4.2. Pill count and bottle weight adherence for mother-infant pairs with > 1 adherence measure. 
  Percent adherence 
Dichotomous 
adherence   
                 n Mean SD* Median     IQR** 
% < 90% 
adherent   
Maternal + Infant regimen       
       Overall  0.87 0.22 0.98 0.82-1.00 33 
       Week 4 1048 0.86 0.23 0.98 0.82-1.00 34 
       Week 12 1024 0.91 0.19 1.00 0.91-1.00 22 
       Week 18 974 0.87 0.19 0.97 0.76-1.00 37 
       Week 28 750 0.82 0.27 0.96 0.74-1.00 40 
  Maternal regimen       
       Overall  0.87 0.21 0.97 0.85-1.00 32 
       Week 4 571 0.86 0.22 0.96 0.82-1.00 37 
       Week 12 552 0.89 0.19 0.98 0.89-1.00 26 
       Week 18 522 0.91 0.17 0.99 0.90-1.00 24 
       Week 28 401 0.81 0.27 0.94 0.73-1.00 42 
  Infant regimen       
       Overall  0.86 0.23 1.00 0.78-1.00 34 
       Week 4 477 0.86 0.24 1.00 0.81-1.00 31 
       Week 12 472 0.92 0.19 1.00 0.95-1.00 17 
       Week 18 452 0.82 0.20 0.87 0.67-1.00 51 
       Week 28 349 0.82 0.27 0.98 0.74-1.00 39 
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  Percent adherence 
Dichotomous 
adherence   
                 n Mean SD* Median     IQR** 
% < 90% 
adherent   
HIV-infected infants        
       Overall  0.84 0.26 0.96 0.83-1.00 41 
       Week 4 30 0.85 0.22 0.93 0.84-1.00 47 
       Week 12 24 0.89 0.22 0.99 0.89-1.00 29 
       Week 18 18 0.82 0.30 0.98 0.75-1.00 39 
    Week 28                                                      11 0.71 0.35 0.83 0.45-1.00 55 
HIV-uninfected infants       
       Overall  0.87 0.22 0.98 0.82-1.00 33 
       Week 4 1018 0.86 0.23 0.99 0.82-1.00 34 
       Week 12 1000 0.91 0.19 1.00 0.91-1.00 22 
       Week 18 956 0.87 0.19 0.97 0.76-1.00 37 
     Week 28 739 0.82 0.27 0.96 0.74-1.00 40   
*SD=standard deviation 
**IQR=Interquartile range 
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Table 4.3.  Characteristics of mother-infant pairs with complete adherence information (n=501) 
  
Always >90% 
adherent (n=146) 
<90% adherent for >1 
interval (n=355) 
Never >90% 
adherent (n=35)* 
  N   % N   % N   % 
ARV randomization 
              Maternal antiretroviral 99 
 
(68) 229
 
(65) 23 
 
(66) 
     Infant nevirapine 47 
 
(32) 126 
 
(35) 12 
 
(34) 
Nutritional randomization 
              No supplement 71
 
(49) 159
 
(45) 17 
 
(49) 
     Received supplement 75 
 
(51) 196 
 
(55) 18 
 
(51) 
Mothers: 
         Age (years) 
              15-25 66
 
(45) 142
 
(40) 18 
 
(51) 
     26-35 78 
 
(53) 187 
 
(53) 17 
 
(49) 
     36-45 2 
 
(1) 25 
 
(7) 0 
 
(0) 
Education 
              Primary school only 90
 
(62) 226
 
(64) 19 
 
(54) 
     More than primary school 55 
 
(38) 129 
 
(36) 16 
 
(46) 
Married 
              No 10
 
(7) 25
 
(7) 1 
 
(3) 
     Yes 136 
 
(93) 330 
 
(93) 34 
 
(97) 
Parity 
              0 22
 
(15) 33
 
(9) 5 
 
(14) 
     >1 124 
 
(85) 321 
 
(91) 30 
 
(86) 
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Always >90% 
adherent (n=146) 
<90% adherent for >1 
interval (n=355) 
Never >90% 
adherent (n=35)* 
 N   % N   % N   % 
CD4+ count per mm3 
              200-350 46
 
(32) 116
 
(33) 11 
 
(31) 
     351-500 41 
 
(28) 110 
 
(31) 11 
 
(31) 
     >500 59 
 
(40) 129 
 
(36) 13 
 
(37) 
Plasma viral load copies/mL       
    <1,000 20  (14) 32  (9) 1  (3) 
    1,001-10,000 42  (29) 93  (26) 3  (9) 
    >10,000 83  (57) 230  (65) 31  (89) 
Hemoglobin (g/dl) 
              <11  74
 
(51) 188
 
(53) 20 
 
(57) 
     >11 72 
 
(49) 167 
 
(47) 15 
 
(43) 
ARV Regimen** 
              Nevirapine based 4
 
(4) 5
 
(2) 1 
 
(4) 
     Nelfinavir based 13 
 
(13) 33 
 
(14) 6 
 
(26) 
     Lopinavir/ritonavir based 82 
 
(83) 191 
 
(83) 16 
 
(70) 
 
Infants 
         Sex 
              Female 67
 
(46) 195
 
(55) 20 
 
(57) 
     Male 79 
 
(54) 160 
 
(45) 15 
 
(43) 
Birth weight (kg) 
              <2.5  17
 
(12) 19
 
(5) 3 
 
(9) 
     >2.5 129 
 
(88) 336 
 
(95) 32 
 
(91) 
* Columns are not mutually exclusive. Those ‘never > 90% adherent’ are also included in the ‘<90% 
adherent for >1 interval’ column. 
**  Among those randomized to maternal ARV arm  
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Table 4.4.  Estimates of adherence as a risk factor for breastmilk HIV-1 transmission and a composite outcome of breastmilk HIV-1 transmission or infant 
death by 38 weeks of age, among those HIV-1 uninfected at 5 weeks.* 
  Imputed adherence    Complete case 
 
Unadjusted 
 
Adjusted** 
 
Unadjusted              Adjusted**  
 
Hazard 
Ratio (95% CI)   
Hazard 
Ratio (95% CI)   
Hazard 
Ratio (95% CI)   
Hazard 
Ratio (95% CI) 
Breastmilk HIV-1 transmission 
            
  
  Maternal and Infant Regimen  
                   Adherent vs non-adherent 0.50 (0.25, 0.99) 
 
0.48 (0.24, 0.97) 
 
0.40 (0.17, 0.91) 
 
0.41 (0.18, 0.94) 
Adherence by study arm 
                    Maternal ARV adherent vs. non-adherent 0.51 (0.21, 1.21) 
 
0.49 (0.20, 1.19) 
 
0.44 (0.17, 1.11) 
 
0.44 (0.17, 1.12) 
     Infant NVP adherent vs. non-adherent 0.48 (0.16, 1.44) 
 
0.47 (0.16, 1.40) 
 
0.31 (0.05, 1.87) 
 
0.32 (0.05, 1.91) 
Breastmilk HIV-1 transmission or infant death 
               Maternal and Infant Regimen 
                   Adherent vs non-adherent 0.58 (0.32, 1.04) 
 
0.59 (0.33, 1.06) 
 
0.42 (0.20, 0.89) 
 
0.44 (0.21, 0.94) 
Adherence by study arm 
                    Maternal ARV adherent vs. non-adherent 0.51 (0.23, 1.08) 
 
0.53 (0.24, 1.17) 
 
0.38 (0.16, 0.91) 
 
0.40 (0.17, 0.95) 
     Infant NVP adherent vs. non-adherent 0.66 (0.28, 1.59)  0.65 (0.27, 1.55)  0.58 (0.13, 2.63)  0.61 (0.13, 2.75) 
*Having greater than or equal to 90% pill count or bottle weight adherence is considered adherent; less than 90% adherence is considered non-adherent. 
**Adjusted for maternal age, CD4+, hemoglobin, and time-dependent reported breastfeeding status. Study arm was included as a confounding variable in 
combined maternal and infant regimen models. Adherence by study arm models included an interaction term between adherence and study arm. 
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CHAPTER FIVE: SPECIFIC AIM 2 RESULTS 
POSTPARTUM ANTIRETROVIRAL ADHERENCE ASSOCIATED WITH REDUCED BREASTMILK HIV-1 RNA 
VIRAL LOAD AND BREASTMILK TRANSMISSION 
 
INTRODUCTION 
Maternal HIV RNA concentration (viral load or VL) in plasma and breastmilk is among the most 
important risk factors for HIV transmission during breastfeeding.(24, 28, 29, 78) Risk of perinatal 
transmission is thought to be virtually 0% at plasma HIV VL less than 1,000 copies/ml, and increase to 
over 40% at plasma HIV VL of more than 100,000 copies/ml.(16) Two potential mechanisms are thought 
to be at play regarding virus populations in breastmilk. The first is by continual trafficking from blood 
into breastmilk of cell-associated virus (measured as HIV-DNA) or cell-free virions (measured as HIV-
RNA).(59) The second is transient local production of virus in the breastmilk.(59, 60) Both cell-associated 
and cell-free virus in breastmilk have been associated with increased breastmilk HIV transmission, and 
no breastmilk HIV RNA threshold has been identified below which breastmilk HIV transmission has not 
occurred.(79, 80)  
 
Breastmilk transmission is thought to occur when infant ingestion of cell-free or cell-associated 
virus in breastmilk is absorbed in mucosal gut surfaces, tonsils, or adenoids.(81) To prevent mother-to-
child HIV transmission (PMTCT), antiretroviral (ARV) interventions have been used to reduce HIV viral 
replication in breastmilk and both maternal and infant blood. Adherence to ARV regimens is necessary 
to achieve and maintain therapeutic drug levels in plasma, and in turn achieve and maintain plasma viral 
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suppression.(33) However, there are differential levels of antiretroviral exposure into breastmilk and 
infant plasma both within and between classes of drugs.(57) Only zidovudine and lamivudine have 
concentrated to any real extent in breastmilk, among the ARVs that have been evaluated to date.(60, 
72) To our knowledge, this study is the first to assess the association between maternal adherence to 
postpartum zidovudine- and lamivudine-containing regimens using ARV pill counts, and resulting 
breastmilk HIV VL. 
 
Greater understanding of the interconnectedness between adherence, breastmilk HIV VL, and 
HIV transmission is a major step in eradicating breastmilk HIV transmission, and making breastfeeding 
safe for all infants. In this study, we will use a comprehensive approach to assess the role of adherence 
on HIV transmission by assessing the causal pathway that includes both maternal plasma and breastmilk 
HIV VL. We will estimate the following associations using clinical data along with stored plasma and 
breastmilk specimens from BAN: 1) postpartum maternal ARV adherence and both maternal plasma and 
breastmilk HIV VL; 2) maternal plasma and breastmilk HIV VL; and 3) breastmilk HIV VL and breastmilk 
HIV transmission.  
 
METHODS 
The Breastfeeding, Antiretrovirals and Nutrition (BAN) randomized trial was conducted in 
Lilongwe, Malawi to assess the benefit and safety of maternal or infant ARV medications to prevent HIV 
transmission during breastfeeding.(7) Mothers were recruited between 2004 and 2010 at antenatal 
clinics. Eligibility criteria for mother-infant pairs included: antibody-confirmed maternal HIV infection, 
maternal CD4 ≥250 cells/µL (≥200 cells/ µL before July 24, 2006), no previous ARV drug use (including 
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single dose NVP), infant birth weight ≥2000 grams, no infant or maternal condition that would preclude 
use of a study drug, and enrollment <36 hours after delivery.(7)   
 
A factorial design was used. Mothers were randomized to receive or not receive a nutritional 
intervention consisting of a lipid-based nutrient supplement throughout breastfeeding.(7) Mother-infant 
pairs were also randomized to receive one of the following postpartum PMTCT prophylaxis regimens: 1) 
28 weeks of maternal triple ARVs (maternal ARV); 2) 28 weeks of infant NVP; or 3) no further drugs 
postpartum (enhanced control).(7) All mothers and infants received one dose of NVP and seven days of 
postpartum zidovudine and lamivudine.(7) Exclusive breastfeeding for the first 24 weeks was advised, 
with weaning between 24 and 28 weeks. (7) Details of the drug regimens and nutrition supplement have 
been reported previously.(71, 75, 76)   
 
Study design 
Using a case-cohort design, we included all mother-infant pairs in the 28 weeks of triple 
maternal ARV or daily infant NVP arms with available plasma or breastmilk samples and an HIV 
transmission event between 2 and 28 weeks of the infant’s life (n=31, 98% of all transmission events). 
We also included a 15% sample of mother-infant pairs randomized to the two treatment arms of BAN 
where HIV transmission did not occur within 28 weeks of life (n=232); sampling was primarily based on 
stored breastmilk and plasma availability. Mother-infant pairs who experienced transmission between 
birth and two weeks of age (n=86) were excluded and information on first-born multiples was used 
when multiple births occurred (n=5). Our analysis thus included a total of 263 mother-infant pairs at risk 
of breastmilk HIV transmission between 2 and 28 weeks of age.  
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Data Analyses 
We considered the following contrasts: 1) adherence and plasma HIV VL, 2) adherence and 
breastmilk HIV VL; 3) plasma and breastmilk HIV VL, and 4) breastmilk HIV VL and breastmilk HIV 
transmission. 
 
Maternal adherence was calculated for the following postpartum time intervals: 2-4 weeks, 8-12 
weeks, and 13-18 weeks. Adherence to triple maternal ARVs was calculated using pill counts taken by 
trained pharmacy staff on contiguous visits.(82) Briefly, maternal ARV adherence was calculated from 
the difference in the number of pills distributed at the previous visit and the number returned at the 
current visit, compared with the number of pills that should have been taken between visits if the 
mother was perfectly compliant. Mothers randomized to the infant NVP arm were assigned a maternal 
adherence value of zero for all intervals. Maternal adherence was categorized into the following using 
disjoint indicator variables, 0-80% (“poor adherence”, referent), 81-98% (“partial adherence”), and >98% 
(“near perfect adherence”). Categories were chosen based on previous studies and the observed 
adherence distribution. (34)  
 
HIV RNA was quantified from blood plasma and whole breastmilk at enrollment, 2, 6, 12, 18, and 
24 weeks postpartum. In addition, breastmilk HIV RNA was measured at 4 and 8 weeks post-delivery. 
Plasma VL was quantified using the Abbott RealTime HIV assay (Abbott Molecular, Des Plaines, IL) and 
the 0.6ml protocol according to the package insert (lower limit of quantitation 40 copies/ml). Breastmilk 
VL was quantified from 0.6 ml whole breastmilk pre-treated with 209ul Abbott RNA sample prep lysis 
buffer and 60ul Abbott Proteinase K (53°C incubation for 20 min) using the Abbott RealTime HIV assay 
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(Abbott Molecular, Des Plaines, IL; lower limit of quantitation 56 copies/ml). HIV RNA concentrations 
that were detected but below the limit of quantitation were assigned a value of 39 for plasma and 55 for 
breastmilk (lower limit of quantitation minus one), and RNA concentrations that were undetectable 
were assigned a value equal to 50% of the lower limit of quantitation (plasma: 20, breastmilk: 28). VL 
was then categorized as detectable (plasma: >40 copies/ml, breastmilk: >56 copies/ml) or undetectable 
(plasma: <40 copies/ml, breastmilk: <56 copies/ml) when treated as a binary variable, and log10-
transformed when treated as a continuous variable. 
 
Infant HIV status was determined at 2, 12, 28, and 48 weeks by Roche Amplicor 1.5 DNA PCR 
(Roche Molecular Systems, Pleasanton, CA, USA). PCR positive results were confirmed by testing an 
additional blood specimen, and the window of infection was narrowed with tests of infant dried blood-
spot specimens taken at 4, 6, 8, 18, 24, and 32 weeks. Breastmilk transmission was defined as first 
detection of HIV infection by PCR in infant blood between 2 and 28 weeks of age. 
 
We used generalized linear mixed models with identity link and Gaussian distribution to 
estimate the difference in log10 plasma VL by adherence category, and logit link with binomial 
distribution to estimate odds ratios for detectable breastmilk VL by adherence and plasma VL category. 
Adherence was paired with VL measured at the end of the adherence time interval to ensure the 
exposure (adherence) occurred prior to the outcome (VL). Therefore, only VL information from 6, 12, 
and 18 weeks postpartum were used when adherence was the exposure. The reciprocal of the study 
inclusion probability was used as a sampling weight in all regression analyses to account for sampling of 
cases and non-cases. 
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Single and multivariable Cox models were used to estimate relative hazard of breastmilk HIV 
transmission by 28 weeks of age. Breastmilk VL was treated as a time-varying covariate in the Cox 
models, lagged by one interval to ensure the exposure occurred prior to the outcome. Mother-infant 
pairs were right censored at the time of infant death, the time of their last PCR negative test if the infant 
was lost to follow-up, or they were administratively censored at 28 weeks if the infant remained HIV-
uninfected during the entire study period. Mother-infant pairs were also censored at reported cessation 
of breastfeeding unless HIV transmission occurred within 30 days of reported cessation.(71)  
 
Effect measure modification was assessed by comparing unadjusted and adjusted hazard ratio 
estimates and 95% confidence intervals using an interaction term between the exposure and variable of 
interest. Covariates that produced adjusted hazard ratio estimates that were different enough to be 
clinically or programmatically relevant were evaluated further as effect measure modifiers. A directed 
acyclic graph (DAG) was used to identify potential confounders and a minimally sufficient adjustment 
set.(77) Potential confounding variables consisted of randomization assignment, demographic 
characteristics, and baseline health status information (Table 5.1). More parsimonious models were 
generated by removal of potential confounders that had minimal effect on the estimate or precision. 
 
Missing adherence and VL measures were accounted for using multiple imputation (83) under 
the assumption the data were missing at random. For each analysis, 50 imputations were performed. 
The imputation model comprised variables believed a priori to be predictive of adherence and VL, and 
for which we had reasonably complete information. Covariates used to predict adherence and VL 
included ARV study arm, maternal age (continuous), parity (0, ≥1), marital status, (married, not married), 
education status (≤ primary, > primary), baseline maternal CD4+ category (200-350, 351-500, >500), 
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baseline maternal hemoglobin (<11 mg, ≥11 mg), baseline maternal log10-transformed VL (continuous), 
previous visit(s) adherence, infant’s HIV status, log of the time until censored if HIV-uninfected or the 
time until HIV transmission occurred if HIV-infected, time-dependent breastfeeding status, time-
dependent plasma VL, and time-dependent breastmilk VL. Logistic regression was used to impute 
dichotomous variables and predictive mean matching was used to impute continuous variables.(84) All 
data analyses were conducted using SAS version 9.3 (SAS Institute, Cary, North Carolina, USA). 
 
RESULTS 
The baseline characteristics of the mother-infant pairs included in this study were comparable 
to those in the full BAN cohort.(7) Most mothers were married (92%) with only a primary education 
(66%) (Table 5.1). The median age was 25 years [interquartile range (IQR): 22 to 29] (Table 5.1). Among 
those in the maternal ARV arm, most received a boosted protease inhibitor regimen of zidovudine, 
lamivudine, and lopinavir boosted with ritonavir (70%). At baseline, mothers had a median CD4+ count 
of 408 per uL (IQR: 301 to 544), median log10 VL of 4.4 copies per ml of blood (IQR: 3.8 to 4.9), and 
median hemoglobin of 10.6 grams per dl (IQR: 9.7 to 11.5). The infants’ median birth weight was 3.0 kg 
(IQR: 2.7 to 3.2).  
 
Among all mothers randomized to maternal ARVs (n=129), overall mean adherence was 88% 
[median 0.96, IQR 0.86-1.00] at 2-18 weeks postpartum. Overall median log10 plasma VL was 2.3 
copies/ml [IQR: 1.6 to 3.5] at 2-24 weeks postpartum among mothers in the maternal ARV arm. The 
percentage of mothers with detectable plasma VL generally decreased over time among mothers 
randomized to maternal ARVs, with 85% (70/82), 77% (86/112), 59% (62/105), 61% (36/59), and 59% 
(47/80) detectable at 2, 6, 12, 18, and 24 weeks respectively. Between 95-100% of mothers randomized 
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to the infant NVP arm (n=134) had detectable plasma VL at any given time point between 2-24 weeks 
postpartum, with a median log10 plasma VL of 4.2 copies/ml [IQR: 3.2 to 4.9].  
 
At 2, 4, 6, 8, 12, 18, and 24 weeks postpartum, the percentage of mothers in the maternal ARV 
arm with detectable breastmilk VL (>56 copies/ml) was 16% (16/103), 18% (18/98), 12% (12/98), 9% 
(9/99), 16% (15/92), 16% (12/77), and 15% (10/65) respectively. Overall, median log10 breastmilk VL 
was 1.7 copies/ml at 2-24 weeks postpartum among mothers in the maternal ARV arm, with 85% 
(539/632) of specimens having virus detected at levels below the lower limit of quantitation. Among 
mothers in the infant NVP arm, median breastmilk VL was 1.7 copies/ml [IQR: 1.7-2.4] at 2-24 weeks 
postpartum, with 15% (16/107) and 37% (41/112) having detectable breastmilk VL at 2 and 4 weeks 
postpartum, respectively; 51-58% had detectable breastmilk VL at 6, 8, 12, 18 and 24 weeks postpartum. 
 
Adherence and HIV viral load 
At least one paired maternal adherence and plasma HIV viral load was available for 245 (93%) 
mothers.  Having partial adherence was associated with a 0.82 (95% confidence interval (CI) 0.55-1.09) 
unadjusted log10 reduction in plasma VL compared to having poor adherence (Table 5.2).  Having near 
perfect adherence was associated with a 0.69 (95% CI 0.45-0.93) unadjusted log10 reduction in plasma 
VL compared to having poor adherence. Adjusting for nutritional randomization and baseline maternal 
characteristics, including age, CD4+ count, and plasma VL resulted in similar associations (partial 
adherence:  -0.93, 95% CI -1.19,-0.68; near perfect adherence:  -0.75, 95% CI -0.98,-0.52). The 
association was comparable although slightly reduced when using multiple imputation.  
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Maternal adherence had an analogous association with suppression of virus in breastmilk. 
Among 211 (80%) mothers with paired adherence and breastmilk HIV VL data, having partial adherence 
was associated with a 76% (95% CI 28-92%) relative reduction in the unadjusted odds of having 
detectable breastmilk VL, compared to having poor adherence (Table 5.2). Having near perfect 
adherence was associated with a 62% (95% CI 14-83%) reduction in the unadjusted odds of having 
detectable breastmilk VL, compared with having poor adherence. Adjustment for potential confounding 
variables did not appreciably change the odds ratio estimates or precision. The associations remained 
similar but less precise when using multiple imputation. 
 
Plasma and breastmilk HIV viral load 
Among the 221 (84%) mothers with ≥1 paired plasma and breastmilk HIV VL, mothers with 
detectable breastmilk VL typically had detectable plasma VL. Two (<1%) mothers had detectable 
breastmilk VL and undetectable plasma VL, both at 6 weeks postpartum with breastmilk VL values of 56 
and 77 copies/ml. Mothers with a detectable plasma VL had 59 (95% CI 21-169) times the unadjusted 
odds of having a detectable breastmilk VL, compared with mothers with an undetectable plasma VL 
(Table 5.3). Adjusting for study arm, baseline maternal CD4+ count, and baseline maternal plasma VL 
resulted in a consistently strong though slightly attenuated association between detectable plasma and 
breastmilk VL (OR 40, 95% CI 15-107). Using multiple imputation produced similar findings.  
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Plasma viral load and HIV transmission 
At least one plasma viral load between 2-24 weeks postpartum was available for 27 of the 33 
(82%) HIV-infected infants. Among these, one transmission event occurred among a mother with 
undetectable baseline plasma viral load. However, transmission did not occur until 24 weeks 
postpartum and occurred after 3 reported viral load measures ranging from 8,000-108,000 copies/ml at 
6, 12, and 24 weeks postpartum. The remaining 25 mothers of infected infants had a baseline plasma 
viral load >3500 copies/ml.  
 
Plasma viral load from the time point immediately preceding transmission was available for 21 
mother-infant pairs, with viral load ranging from 102 to >636,000 copies/ml. All 27 mothers who 
transmitted HIV during 2-28 weeks postpartum had ≥1 plasma VL >100 copies/ml. 
 
Complete time-dependent maternal plasma viral load and infant HIV status information was 
available for 116 mother-infant pairs. Of these, 8 experienced a HIV-1 transmission event between 2-28 
weeks postpartum (maternal ARV arm: 6, infant NVP arm: 2). No transmission occurred among mothers 
with undetectable plasma viral load.  
 
Among the 116 mothers with complete maternal plasma viral load information, 5 had 
undetectable plasma VL at all measured time points. Of these 5, all also had undetectable breastmilk 
viral load at all measured time points.  
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Breastmilk viral load and HIV transmission 
Complete time-dependent breastmilk VL and infant HIV status were available for 134 (51%) 
mother-infant pairs. Of these, 15 experienced a HIV transmission event between 2-28 weeks 
postpartum (maternal ARV arm: 11, infant NVP arm: 4). Eleven of the 15 mothers (73%) had at least one 
detectable breastmilk VL before transmission occurred, and 8 of the 15 mothers (53%) had a detectable 
breastmilk VL at the last measured time point before transmission occurred. Having a detectable 
breastmilk VL was associated with 2.7 (95% CI 1.4, 5.4) times the unadjusted rate of breastmilk HIV 
transmission, compared with having an undetectable breastmilk VL (Table 5.4). A much stronger though 
less precise association was estimated after adjusting for study arm and baseline maternal 
characteristics including age, CD4+ count, hemoglobin, and plasma VL (HR 7.4, 95% CI 3.2-17.1). Using 
multiply imputed data, detectable breastmilk VL had a similar unadjusted and somewhat diminished 
adjusted association with HIV transmission (unadjusted HR 2.9, 95% CI 1.0-8.4; adjusted HR 3.8, 95% CI 
1.2-12.1). 
 
DISCUSSION 
We have shown that antiretroviral adherence is associated with reduced breastmilk HIV 
transmission, at least partly mediated by reduced maternal plasma and breastmilk HIV RNA 
concentration. In addition, we found a strong association between having detectable maternal plasma 
and breastmilk HIV RNA, and have shown that breastmilk HIV VL is associated with breastmilk HIV 
transmission between 2-28 weeks of infant’s life among women or infants receiving ARVs. We were able 
to detect HIV RNA at lower concentrations than several previous studies, but were unable to identify a 
breastmilk HIV RNA threshold below which transmission did not occur.  
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Non-adherence to ART has been associated with higher plasma HIV VL in pregnant women. 
Similarly, we found non-adherence to postpartum maternal ARVs to be associated with significantly 
higher plasma and breastmilk HIV RNA concentration during the breastfeeding period, and provide the 
first estimates of the association between maternal antiretroviral adherence and breastmilk HIV VL. In 
addition, plasma VL has been correlated with breastmilk VL.(29, 41, 43, 85)  Using more frequently 
measured paired plasma and breastmilk specimens, we also found a strong positive association between 
plasma and breastmilk HIV RNA concentration.  
 
The relative contribution of cell-associated (DNA) versus cell-free (RNA) breastmilk VL toward 
breastmilk HIV transmission remains unclear. Cell-free virus has been shown to be more important for 
HIV transmission at later stages of breastfeeding, while cell-associated virus has been found to be more 
important in the first months of breastfeeding.(79, 80) We assessed the association between HIV RNA 
levels in breastmilk and resulting HIV transmission using a larger sample of mothers, and more frequent 
measures of time-dependent breastmilk HIV RNA than previously reported studies. In addition, we used 
methods to take into account missing adherence and VL, infants lost to follow-up, and infant death. We 
found a strong association between breastmilk VL and breastmilk HIV transmission at 2-28 weeks of 
infant’s age, suggesting that HIV RNA levels in breastmilk is an important risk factor for breastmilk HIV 
transmission in the first 7 months of breastfeeding.  
 
The adherence levels and breastmilk HIV RNA concentration found in BAN (among mothers 
receiving and not receiving maternal ARVs) are similar to levels found in previous studies.(4, 8, 80, 85-
87) Making direct comparisons, however, is difficult due to differences in adherence measurement and 
viral assays, and the variety of thresholds used to define adherence and detectable VL. Most studies 
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measure adherence using self-report, which is known to be subject to recall and social desirability bias. 
We used pill count adherence, which is subject to patient manipulation but is thought to have greater 
validity than self-reported adherence. However, we previously found a consistent association between 
adherence and breastmilk HIV transmission in BAN using both pill count and maternal self-reported 
adherence.(82) In addition, the lower limit of RNA quantitation varies by viral assay used, and thresholds 
for defining detectable viral load have ranged from concentration levels greater than the lower limit of 
quantitation to concentration levels above the median log10 viral load found among study subjects.  
 
Detectable breastmilk HIV VL and breastmilk HIV transmission occurred despite perfect (100%) 
maternal ARV pill count adherence, potentially due to imperfection in our adherence measure, the 
length of time between maternal initiation of antiretrovirals and viral suppression, mastitis, 
antiretroviral drug resistance, or other unidentified processes. Breastmilk HIV transmission also 
occurred despite undetectable breastmilk HIV VL, possibly due to persistent cell-associated HIV viral 
reservoirs in breastmilk which are not eliminated under triple ARV drug pressure. (88-91)  
 
There was inconsistency in the time intervals between scheduled visits, and therefore in the 
amount of weeks between adherence and viral load measures. In addition, only contiguous visits for 
which pill count information was collected could be used to measure adherence, resulting in extended 
time intervals between measures. Adherence was held constant during the interval, and therefore may 
not reflect the true adherence at the time immediately preceding the VL measure. Similarly, measured 
VL may not be the true VL at the time immediately preceding transmission. Holding adherence and VL 
constant during the interval may have resulted in reduced variance. We did not use methods that take 
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into account interval censoring, however interval censoring methods made little difference in previous 
BAN analyses.(7)  
 
Slightly stronger associations between adherence and both plasma and breastmilk VL were 
estimated in the partial adherent group, compared to the near perfect adherence group. The 
paradoxical result between adherence and VL among those with near perfect (>98%) adherence may be 
due to measurement error in our adherence measure. However, both adherence categories were 
associated with reduced plasma and breastmilk HIV-RNA concentration. The likely presence of some 
adherence measurement error reinforces the difficulty of obtaining accurate adherence estimates even 
in heavily monitored clinical trials, and the need for simple and accurate adherence measurement tools.  
 
The limited number of available paired adherence and VL measures among mothers in the 
maternal ARV arm affected the precision of our estimates, and limited our ability to make conclusions by 
ARV study arm. Missing adherence and VL measures were multiply imputed. Similar but slightly reduced 
associations were seen for all contrasts when multiply imputed data were used. No substantial gains in 
precision were seen when using multiply imputed data, potentially due to the number of outcomes that 
had to be imputed and the lack of strong auxiliary variables.(92) However, mixed effects models 
produce valid inferences despite missing data on the dependent variable, provided the data are missing 
at random. The consistency in our estimates using both complete case and multiply imputed data 
increase the confidence in our findings.  
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As we have previously shown, antiretroviral adherence needs to be maintained to maximize 
efforts to prevent mother-to-child transmission and increase HIV-free survival.(82) However, we now 
more conclusively show that maintaining antiretroviral adherence alone is not likely to prevent all of 
breastmilk transmission. The sufficient set of mechanisms that cause breastmilk HIV transmission 
remain incompletely determined. Provision of lifelong maternal ART to all pregnant and breastfeeding 
women, with the ARVs currently available, will likely have to be implemented in concert with other 
prevention interventions to fully eliminate breastmilk HIV transmission.(93)  
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Table 5.1. Baseline characteristics of 263 mother-infant pairs.  
 
Total* 
 N   (%) 
Antiretroviral randomization 
        Maternal antiretroviral 129 
 
(49) 
     Infant nevirapine 134 
 
(51) 
Nutritional randomization 
        No supplement 125 
 
(48) 
     Received supplement 138 
 
(52) 
Mothers: 
   Age (years) 
        15-25 144 
 
(55) 
     26-35 105 
 
(40) 
     36-45 13 
 
(5) 
Education 
        Primary school only 173 
 
(66) 
     More than primary school 90 
 
(34) 
Married 
        No 21 
 
(8) 
     Yes 242 
 
(92) 
Parity 
        0 36 
 
(14) 
     ≥1 227 
 
(86) 
CD4+ count per mm3 
        200-350 95 
 
(36) 
     351-500 81 
 
(31) 
     >500 87 
 
(33) 
Plasma viral load copies/ml 
      ≤ 1,000 20 
 
(8) 
   1,001-10,000 60 
 
(23) 
   > 10,000 181 
 
(69) 
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 Total* 
 N  (%) 
Hemoglobin (g/dl) 
        < 11  160 
 
(61) 
     ≥ 11 103 
 
(39) 
ARV Regimen** 
        Nevirapine based 5 
 
(4) 
     Nelfinavir based 29 
 
(26) 
     Lopinavir/ritonavir based 78 
 
(70) 
Infants 
   Sex 
        Female 139 
 
(53) 
     Male 124 
 
(47) 
Birth weight (kg) 
        <2.5 27 
 
(10) 
     ≥2.5 236  (90) 
*Maternal age is missing for 1 mother, baseline plasma viral load 
is missing for 2 mothers, and ARV regimen is missing for 17 
mothers assigned to maternal ARVs  
**Among mothers randomized to maternal ARV arm 
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Table 5.2.  Estimates of adherence as a risk factor for plasma and breastmilk HIV-1 viral load (VL) 
    Complete case   Imputed 
  
Unadjusted 
 
        Adjusted* 
 
Unadjusted 
  
 Adjusted* 
    
Beta;  
Odds 
Ratio† (95% CI) 
Beta;  
Odds 
Ratio† (95% CI) 
Beta;  
Odds 
Ratio† (95% CI) 
Beta;  
Odds 
Ratio† (95% CI) 
Maternal plasma VL 
             Maternal and Infant Arm 
               Partial vs poor adherence 
 
-0.82 (-1.09, -0.55) -0.93 (-1.19, -0.68) -0.45 (-0.76, -0.15) -0.52 (-0.82, -0.22) 
Near perfect vs. poor 
adherence 
 
-0.69 (-0.93, -0.45) -0.75 (-0.98, -0.52) -0.37 (-0.65, -0.08) -0.42 (-0.70, -0.15) 
              Maternal arm only 
               Partial vs poor adherence 
 
-0.07 (-0.45, 0.30) -0.08 (-0.45, 0.29) 0.01 (-0.31, 0.33) 0.01 (-0.31, 0.33) 
  Near perfect vs. poor 
adherence 
 
0.09 (-0.25, 0.44) 0.10 (-0.24, 0.44) 0.11 (-0.19, 0.41) 0.12 (-0.18, 0.41) 
              Breastmilk VL 
             Maternal and Infant Arm 
               Partial vs poor adherence 
 
0.24 (0.08, 0.72) 0.23 (0.08, 0.67) 0.30 (0.07, 1.30) 0.29 (0.07, 1.19) 
Near perfect vs. poor 
adherence 
 
0.38 (0.17, 0.86) 0.36 (0.16, 0.81) 0.42 (0.10, 1.83) 0.41 (0.10, 1.69) 
              Maternal arm only 
               Partial vs poor adherence 
 
0.47 (0.16, 1.41) 0.47 (0.15, 1.40) 0.50 (0.11, 2.21) 0.50 (0.11, 2.21) 
Near perfect vs. poor 
adherence   0.64 (0.28, 1.43) 0.64 (0.29, 1.43) 0.67 (0.15, 2.96) 0.68 (0.15, 3.00) 
*Adjusted for: baseline maternal age, baseline maternal CD4 count, baseline log10 plasma viral load, and nutrition randomization 
  † Beta coefficient (average difference in log10 plasma viral load) presented for mixed linear regression plasma VL results and odds ratio presented for 
mixed logistic regression breastmilk VL results 
 
 
  
 
  
7
9
 
Table 5.3.  Estimates of detectable plasma viral load  as a risk factor for detectable breastmilk viral load 
    Complete Case    Imputed 
  
Unadjusted 
 
Adjusted* 
 
Unadjusted 
 
Adjusted* 
    
Odds 
Ratio (95% CI)   
Odds 
Ratio (95% CI)   
Odds 
Ratio (95% CI)   
Odds 
Ratio (95% CI) 
Maternal and Infant Arm 
                   Detectable vs. Undetectable 
 
59 (21, 169) 
 
40 (15, 107) 
 
43 (8, 236) 
 
35 (7, 169) 
Maternal arm only 
                   Detectable vs. Undetectable   45 (16, 124)   40 (15, 108)   41 (9, 185)   38 (9, 168) 
* Adjusted for baseline maternal CD4+ and baseline maternal plasma viral load. Study arm was included as a confounding  
    variable in combined maternal and infant arm models, but was not included in maternal arm only models. 
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 Table 5.4.  Estimates of detectable breastmilk HIV viral load as a risk factor for breastmilk HIV-1 transmission 
  Complete Case                                Imputed 
 
Unadjusted* 
 
      Adjusted** 
 
Unadjusted* 
 
Adjusted** 
  
Hazard 
Ratio (95% CI) 
Hazard 
Ratio (95% CI) 
Hazard 
Ratio (95% CI)   
Hazard 
Ratio (95% CI) 
DICHOTOMOUS VIRAL LOAD 
            Maternal and Infant Arm 
               Detectable vs. Undetectable 2.7 (1.4, 5.4) 7.4 (3.2, 17.1) 2.9 (1.0, 8.4) 3.8 (1.2, 12.1) 
Viral load by study arm 
               Maternal ARV: Detectable vs. Undetectable 5.6 (2.5, 12.7) 7.8 (3.1, 19.2) 4.8 (1.5, 15.8) 4.4 (1.3, 15.2) 
   Infant NVP: Detectable vs. Undetectable 3.9 (0.8, 18.0) 6.0 (1.2, 31.4) 2.8 (0.5, 15.0) 2.9 (0.5, 17.7) 
*Combined maternal and infant arm models contained no confounding variables. Viral load by study arm models contained study arm and an interaction 
term between breastmilk viral load and study arm. 
**Adjusted for continuous baseline maternal age, baseline maternal CD4+, baseline maternal hemoglobin level, and baseline maternal plasma viral load. 
Study arm was included as a confounding variable in combined maternal and infant arm models. Viral load by study arm models included an interaction 
term between breastmilk viral load and study arm. 
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CHAPTER SIX: CONCLUSIONS 
 
  Postpartum HIV transmission through breastfeeding accounts for up to 44% of infant HIV 
infections.(23) ARVs can be safely given throughout breastfeeding to reduce HIV transmission risk, as 
demonstrated in clinical trials. However, transmission still occurs despite the use of efficacious drug 
regimens. Transmission may partly be explained by suboptimal adherence to prescribed ARV regimens. 
The purpose of this dissertation was to 1) estimate adherence to postpartum ARVs, 2) quantify the 
effect of postpartum adherence on breastmilk HIV transmission, and 3) evaluate breastmilk HIV RNA 
concentration as a mediating factor between ARV adherence and breastmilk HIV transmission. 
 
We showed that while on average postpartum adherence remained high, between 22-40% of 
mother-infant pairs had intermittent periods of non-adherence. We further showed that non-adherence 
to antiretroviral regimens is strongly associated with increased breastmilk HIV transmission, and that 
adherence needs to be maintained throughout the breastfeeding period to maximize efforts to prevent 
transmission and improve infant HIV-free survival. In addition, we found the association between 
antiretroviral adherence and breastmilk HIV transmission to be at least partly mediated by reduced 
breastmilk HIV RNA concentration. Non-adherence, however, did not explain all of the transmissions 
that occurred, suggesting that other biological mechanisms not affected by ARV use may also be at play. 
This research adds to the scant literature on postpartum ARV adherence and adherence-related 
mechanisms of breastmilk HIV transmission. 
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The strong relationship between postpartum ARV adherence and HIV transmission has several 
important practical implications. Transmission outcomes seen in closely monitored clinical trials with 
relatively high mean ARV adherence are used to produce global modeling and local PMTCT program 
effectiveness estimates of vertical HIV transmission rates. However, adherence is likely to be lower 
outside of a clinical trial setting, potentially resulting in larger numbers of HIV-infected infants in need of 
ART than projected. In addition, most PMTCT studies have stopped postpartum ARVs at or before 6 
months, with recommended concurrent breastfeeding cessation. However, HIV-positive mothers are 
now encouraged to continue breastfeeding for the first 12 months of life to avoid malnutrition and an 
increased risk of serious infant infections due to unsafe feeding practices.(32) Estimates of adherence 
and transmission probabilities among women receiving ARVs through one to two years of breastfeeding 
are needed in order to more accurately estimate transmission rates and forecast pediatric ART needs. 
Therefore, validating model projections with program data will be needed, which will require increased 
focus and support of national monitoring and evaluation systems. 
 
 
Partly to prevent vertical HIV transmission, WHO now recommends that all pregnant and 
breastfeeding women be initiated on lifelong ART, and receive the same first-line drug regimen 
(tenofovir, lamivudine, and efavirenz) as non-pregnant adults.(32) The benefits of such an approach are 
many. PMTCT programs have been plagued by complicated protocols, with various ARV prophylaxis 
options being offered depending on when HIV diagnosis is made, how many weeks the mother receives 
ARVs, and the severity of maternal disease. In contrast, this one size fits most approach (in some 
circumstances, ART is stopped after breastfeeding cessation) greatly simplifies treatment instructions to 
health care workers, and treatment messaging to women. In addition, it simplifies national-level drug 
forecasting. Initiating all pregnant and breastfeeding women on ART regardless of immunological status 
 
  
83 
  
also removes the barrier that the lack of CD4 testing created in so many resource-limited settings, and 
ensures that all women with acute infection and advanced disease are immediately initiated on 
treatment. Immediate treatment initiation can improve maternal health by delaying disease 
progression, and can reduce transmission risk to both the mother’s sexual partners and infant.  
 
 
Roll-out of current WHO recommendations to extend ARV prophylaxis through breastfeeding 
and beyond depends on health facilities’ ability to retain patients in HIV care, and on patient adherence 
to lifelong ART. Retention and adherence in PMTCT settings have been long-standing obstacles to the 
success of national PMTCT programs. Malawi was the first country to implement lifelong ART to all 
pregnant and breastfeeding women. On average, 17% of women initiated on lifelong ART were lost to 
follow-up by 6 months after initiation.(94) The lost to follow-up rate was as high as 58% by 6 months 
post-ART initiation at some high-volume facilities, although some women may have sought care at 
another clinic. Facilities that offered adherence counseling beyond that required by national guidelines 
experienced lower rates of early lost to follow-up.(94)  
 
 
Introducing maternal ART at higher CD4+ counts without simultaneous improvements in health 
system performance (i.e.: access to ANC services, HIV counseling and testing, and ART) resulted in 
limited reductions in the modeled number of HIV-infected infants by six weeks of age.(95) Neither 
postpartum transmission nor acute maternal infections were included in the model, and provision of 
ART to all pregnant women regardless of CD4+ count was not included as a prophylaxis option. Including 
breastmilk transmission events and provision of ART to all HIV-infected breastfeeding mothers 
regardless of CD4+ count would likely reveal to an even greater extent the negative impact that health 
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system inefficiencies occurring through years of breastfeeding transmission risk have on achieving 
PMTCT program goals. 
 
 
Countries that require CD4+ counts as part of ART eligibility criteria for pregnant and 
breastfeeding women have necessitated between 9-16+ visits per pregnancy in order for mothers and 
infants to receive comprehensive care (Table 6.1). Each clinic visit has time and financial costs for the 
mother, making it easy to understand why so many pregnant women, mothers, and children are lost to 
follow-up at each stage of the PMTCT cascade. The number of required clinic visits for a mother and 
infant to receive comprehensive care needs to be reduced, without sacrifices to quality of care or overall 
morbidity and mortality. Adherence seems to be improved with increased counseling, requiring a 
balance between creating a system with minimal clinic visit requirements yet regular adherence 
counseling opportunities. This may require more effective clinic-based adherence messages that have a 
longer lasting effect on pill-taking behavior, or simple and effective non-clinic-based adherence 
interventions that can be implemented over mobile devices (i.e.: text message) or by home visits from 
community partners. Being able to predict who will likely be non-adherent would help in developing 
tailored and targeted adherence interventions, and to offer an adherence intervention before 
transmission occurs. We found no baseline covariates to be consistently associated with non-adherence 
in our study, suggesting that prediction of non-adherence may be challenging. Consequently, a more 
generic intervention that is simple and can be applied to everyone may be required in some settings. 
Due to changes in adherence seen over time, adherence interventions need to be offered throughout 
one to two years of breastfeeding. To ensure maximal benefit, a variety of effective adherence 
interventions will likely be needed to ensure patients do not become desensitized to messaging.   
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We have shown that accurately and consistently measuring adherence is difficult even in a 
clinical trial with intensive monitoring and follow-up. Self-reported adherence measurements, thought 
to be the easiest and most affordable way to measure adherence, were missing for a large number of 
patients. Pill count and bottle weight adherence are thought to be more accurate than self-reported 
adherence. However, we found some pill count and bottle weight adherence values less than zero and 
more than 100 percent, signaling some measurement error even with measurements that are not 
thought to be as subject to social desirability bias. Accurately and consistently measuring adherence to 
ART throughout breastfeeding and beyond, in both highly regulated clinical trials and ‘real-world’ health 
facility settings, is crucial information for global, national, and facility-level PMTCT programs. Therefore, 
innovative, simple, and feasible adherence measurement tools are urgently needed.  
 
Poor antiretroviral adherence can lead to antiretroviral drug resistance. Protease inhibitors have 
a higher genetic barrier to resistance, as several mutations are required before resistance develops.(36)   
A single mutation is enough to confer high-level resistance to NNRTI-based regimens.(96)  In addition, 
NNRTIs typically have a longer half-life than PIs, resulting in potential mono-therapy and development of 
drug resistance if patients are non-adherent for extended periods of time.(36) A protease inhibitor-
based ARV regimen was prescribed to most (80%) of the mothers randomized to maternal ARVs in our 
cohort study. However, the WHO recommended first line regimen for pregnant and breastfeeding 
women contains a NNRTI backbone (efavirenz) and no protease inhibitors, making adherence crucial to 
the success of initiating all pregnant and breastfeeding women on ART. Among mother-infant pairs with 
complete adherence information in our study, 71% were non-adherent during at least one time interval. 
The intermittent intervals of sub-optimal (<90%) adherence found in our study, in combination with the 
high percentage of mothers lost to follow-up in some PMTCT programs, make resistance a valid concern 
for operationalizing current WHO guidance. Accurately and consistently measuring adherence to ART 
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will help to ascertain if a patient’s virological failure is due to non-adherence (signaling a needed 
adherence intervention) or drug resistance (signaling a needed ARV regimen switch). 
 
Currently available ARV drugs have not successfully eliminated cell-associated viral reservoirs in 
breastmilk. Cell-associated virus has been associated with higher breastmilk transmission, especially 
during the first months of breastfeeding when breastmilk contains more cells. Provision of maternal 
ARVs to all pregnant and breastfeeding women is therefore unlikely to eliminate all transmission unless 
new ARV drugs that eliminate cell-associated reservoirs are developed.(93)  
 
 
In conclusion, with ARVs we can reduce vertical and sexual transmission by >96 percent.(74, 97) 
Operational research has simultaneously shown us that effective provision of ARV prophylaxis or 
treatment to pregnant and breastfeeding women is hampered by health system constraints and societal 
norms. In order to make breastfeeding safe for all infants, and to fully eliminate new infant HIV 
infections, we must answer the difficult operational question of how to implement lifelong efficacious 
drug regimens with the same rigor, hope, and creativity that is used to answer the scientific question of 
how to biologically prevent transmission.  
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Table 6.1. Example of a list of visits a HIV-infected pregnant woman/mother needs to make in order 
 to receive comprehensive care* 
Visit number Service provided 
1 1st ANC visit 
2 CD4 collection 
3 CD4 result (if lower than ART threshold then go to ART clinic for evaluation) 
4 1st of 2 pre-treatment counseling appointments 
5 2nd of 2 pre-treatment counseling appointments 
6 Initiate treatment 
7 Return for hemoglobin test 2 weeks post-ART initiation 
8 2nd ANC visit 
9 3rd ANC visit 
10 Delivery 
11 1 week post-natal exam 
12 6 week post-natal exam and early infant HIV diagnosis 
13 Return for infant HIV test results 
14 4 month immunization visit 
15 9 month immunization visit 
16 Multiple returns for repeat infant HIV testing, drug refills, and ART management 
appointments 
*Based on actual visit schedule in a sub-Saharan African country, 2009 
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